Catalytic Enantioselective Tautomerization of Metastable Enamines

Jingjing Liu,[‡] Xin Yang,[‡] Zhijun Zuo, Jiang Nan, Yaoyu Wang, and Xinjun Luan*

Key Laboratory of Synthetic and Natural Functional Molecule Chemistry of the Ministry of Education, College of Chemistry & Materials Science, Northwest University, Xi'an 710127, China

[§]J.L. and X.Y. contributed equally to this work.

Supporting Information

Table of Contents

A.	General information:	S1
B.	Preparation of the biaryl coupling partner 1b-u:	S2
C.	Preparation of the enamines 3:	S9
D.	Preliminary studies on the stability of enamine 3a:	S21
E.	Catalytic results:	S21
F.	Further studies on the catalytic enantioselective tautomerization of enamine 3d:	S34
G.	Absolute stereochemistry assignment:	S34
H.	References:	S35
I.	NMR Spectra and HPLC:	

A. General information:

All reactions were carried out under an argon atmosphere using Standard Schlenk-Lines or a glovebox (Innovative Technology). All reagents were used as received unless otherwise noted. DMF, DCM, DCE, CHCl₃ and DMSO were dried over CaH₂. Toluene, (trifluoromethyl)benzene, *m*-xylene, *o*-xylene, *n*-hexane and THF were dried over sodium. Analytical thin-layer chromatography was performed with 0.25 mm coated commercial silica gel plates (TLC Silica Gel 60 F₂₅₄); visualization of the developed chromatogram was performed by fluorescence. Flash Chromatography was performed with silica gel (300-400 mesh) or basic alumina (200-300 mesh, pH \approx 9.0). Proton nuclear magnetic

resonance (¹H NMR) data were acquired on a Varian Unity Inova-400 (400 MHz) or Bruker Ascend 400 (400 MHz) spectrometer, and chemical shifts are reported in delta (δ) units, in parts per million (ppm) downfield from tetramethylsilane. Splitting patterns are designated as s, singlet; d, doublet; t, triplet; q = quartet; m, multiplet, coupling constants *J* are quoted in Hz. Carbon-13 nuclear magnetic resonance (¹³C NMR) data were acquired at 100 MHz on a Varian Unity Inova-400 or Bruker Ascend 400 (400 MHz) spectrometer, and chemical shifts are reported in ppm relative to the center line of a triplet at 77.0 ppm for chloroform-*d*. Fluorine nuclear magnetic resonance (¹⁹F NMR) data were acquired at 376 MHz on a Bruker Ascend 400 (400 MHz) spectrometer, and chemical shifts are reported relative to inter standard CFCl₃ at 0.0 ppm. Infrared spectra were recorded on a TENSOR 27 FT-IR spectrophotometer and reported in wave numbers (cm⁻¹). High resolution mass spectra were acquired on a Bruker Daltonics MicroTof-Q II mass spectrometer. HPLC analyses were performed on an Agilent Technologies 1260. Optical rotations were measured on a Rudolph Research Analytical Autopol II automatic polarimeter. **1a**¹ and **2b-1**²⁻⁵ were prepared according to literature methods.

B. Preparation of the biaryl coupling partner 1b-u:

(I) General method A:



A 50 mL round bottom flask with a stir bar was fitted with a rubber septum and flame dried under high vacuum. The flask was purged with argon and charged with $Pd(PPh_3)_4$ (0.15 g, 0.13 mmol), K_2CO_3 (0.69 g, 5.0 mmol), (2-bromophenyl)boronic acid (0.60 g, 3.0 mmol), *ortho*-iodoaniline derivatives (2.5 mmol), deoxygenated 1,4-dioxane (13.0 mL) and deoxygenated water (2.5 mL). The mixture was stirred at 80 °C until the reaction was judged to be completed by TLC analysis. Water was added and extracted with EtOAc. The organic phase was dried over anhydrous MgSO₄ and concentrated under reduced pressure. The residue was then chromatographed on silica gel (petroleum ether/ethyl acetate) to afford the 2'-bromo-[1,1'-biphenyl]-2-amine derivative **1**.

(II) General method B:



A 50 mL round bottom flask with a stir bar was fitted with a rubber septum and flame dried under high vacuum. The flask was purged with argon and charged with $Pd(PPh_3)_4$ (0.17 g, 0.15 mmol), K_2CO_3 (0.83 g, 6.0 mmol), 2-(4,4,5,5-tetramethyl-1,3,2-dioxabrolan-2-yl)aniline derivative (3.0 mmol), the corresponding dihalogenated aryl derivatives (3.6 mmol), deoxygenated 1,4-dioxane (15.0 mL) and deoxygenated water (3.0 mL). The mixture was stirred at 80 °C until the reaction was judged to be completed by TLC analysis. Water was added and extracted with EtOAc. The organic phase was dried over anhydrous $MgSO_4$ and concentrated under reduced pressure. The residue was then chromatographed on silica gel (petroleum ether/ethyl acetate) to afford the 2'-bromo-[1,1'-biphenyl]-2-amine derivative **1**.



2'-Bromo-5-methyl-[1,1'-biphenyl]-2-amine (1b)

Compound 1b was prepared from 2-iodo-4-methylaniline by using Method A.

1b (Red solid, 0.56 g, 85% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.60 (dd, J = 8.0, 1.0 Hz, 1H), 7. 31 – 7.27 (m, 1H), 7.23 (dd, J = 7.6, 1.9 Hz, 1H), 7.18 – 7.11 (m, 1H), 6.94 (dd, J = 8.1, 1.8 Hz, 1H), 6.77 (d, J = 1.5 Hz, 1H), 6.62 (d, J = 8.1 Hz, 1H), 3.31 (s, 2H), 2.20 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 141.0, 140.2, 133.0, 131.9, 130.6, 129.7, 129.2, 127.8, 127.6, 127.4, 124.2, 115.8, 20.5. IR (KBr): 3457, 3371, 3017, 2919, 1618, 1432, 1257, 751 cm⁻¹. HRMS (ESI) m/z calculated for $C_{13}H_{13}BrN [M+H]^+ 262.0231$, found 262.0231.



2'-Bromo-5-isopropyl-[1,1'-biphenyl]-2-amine (1c)

Compound 1c was prepared from 2-iodo-4-isopropylaniline by using Method A.

1c (Red solid, 0.50 g, 69% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.69 (d, J = 8.0 Hz, 1H), 7.42 – 7.32 (m, 2H), 7.26 – 7.20 (m, 1H), 7.08 (dd, J = 8.2, 2.0 Hz, 1H), 6.90 (d, J = 1.8 Hz, 1H), 6.73 (d, J = 8.2 Hz, 1H), 3.43 (s, 2H), 2.93 – 2.79 (m, 1H), 1.23 (d, J = 6.9 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 141.4, 140.4, 138.8, 133.1, 131.9, 129.2, 128.3, 127.8, 127.1, 127.0, 124.4, 115.6, 33.2, 24.3, 24.2. IR (KBr): 3450, 3054, 2957, 1617, 1463, 1420, 1260, 746 cm⁻¹. HRMS (ESI) m/z calculated for C₁₅H₁₇BrN [M+H]⁺ 290.0544, found 290.0544.



2'-Bromo-5-(tert-butyl)-[1,1'-biphenyl]-2-amine (1d)

Compound 1d was prepared from 2-iodo-4-(tert-butyl)aniline by using Method A.

1d (Red solid, 0.57 g, 75% yield).¹H NMR (400 MHz, CDCl₃): δ 7.70 (d, J = 7.8 Hz, 1H), 7.39 – 7.37 (m, 2H), 7.25 – 7.22 (m, 2H), 7.05 (d, J = 2.3 Hz, 1H), 6.74 (d, J = 8.4 Hz, 1H), 3.44 (s, 2H), 1.30 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 140.0, 139.9, 139.4, 132.1, 130.8, 128.0, 126.7, 126.4, 125.6, 124.8, 123.3, 114.2, 32.9, 30.5. IR (KBr): 3460, 3375, 3055, 2958, 1618, 1467, 1363, 1261, 753 cm⁻¹. HRMS (ESI) m/z calculated for C₁₆H₁₈BrNNa [M+Na]⁺ 326.0520, found 326.0508.



2"-Bromo-[1,1':3',1"-terphenyl]-4'-amine (1e)

Compound **1e** was prepared from 3-(4,4,5,5-tetramethyl-1,3,2-dioxabrolan-2-yl)-[1,1'-biphenyl]-4-amine by using Method B.

1e (White solid, 0.75 g, 77% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.74 – 7.70 (m, 1H), 7.59 – 7.55 (m, 2H), 7.48 (dd, J = 8.3, 2.2 Hz, 1H), 7.42 – 7.36 (m, 4H), 7.32 (d, J = 2.2 Hz, 1H), 7.28 –7.24 (m, 2H), 6.86 (d, J = 8.3 Hz, 1H), 3.62 (s, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 143.1, 140.9, 139.9, 133.3, 132.0, 131.2, 129.5, 129.0, 128.8, 128.0, 127.8, 127.4, 126.5, 126.4, 124.3, 116.0. IR (KBr): 3468, 3379, 3033, 2923, 1615, 1478, 1263, 754 cm⁻¹. HRMS (ESI) m/z calculated for C₁₈H₁₄BrNNa [M+Na]⁺ 346.0207, found 346.0222.



2'-Bromo-5-methoxy-[1,1'-biphenyl]-2-amine (1f)

Compound **1f** was prepared from 2-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) aniline by using Method B.

1f (Yellow solid, 0.50 g, 60% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.68 (d, J = 8.0 Hz, 1H), 7.38 (t, J = 7.4 Hz, 1H), 7.32 (dd, J = 7.6, 1.8 Hz, 1H), 7.23 (td, J = 7.7, 2.0 Hz, 1H), 6.81 (dd, J = 8.7, 2.9 Hz, 1H), 6.72 (d, J = 8.7 Hz, 1H), 6.62 (d, J = 2.9 Hz, 1H), 3.75 (s, 3H), 3.28 (s, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 152.4, 140.0, 137.3, 133.1, 131.7, 129.3, 128.3, 127.9, 124.0, 117.0, 115.4, 115.1, 55.8. IR (KBr): 3443, 3361, 3052, 2939, 1611, 1503, 1273, 752 cm⁻¹. HRMS (ESI) m/z calculated for C₁₃H₁₃BrNO [M+H]⁺ 278.0181, found 278.0174.



2'-Bromo-5-fluoro-[1,1'-biphenyl]-2-amine (1g)

Compound 1g was prepared from 4-fluoro-2-iodoaniline by using Method A.

1g (Red oil, 0.47 g, 70% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.67 (d, J = 8.0 Hz, 1H), 7.36 (t, J = 7.4 Hz, 1H), 7.27 (dd, J = 7.6, 1.7 Hz, 1H), 7.26 – 7.19 (m, 1H), 6.90 (td, J = 8.5, 2.9 Hz, 1H), 6.76 (dd, J = 8.9, 2.9 Hz, 1H), 6.67 (dd, J = 8.8, 4.8 Hz, 1H), 3.39 (s, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 155.4 (d, J = 236.3 Hz), 139.6 (d, J = 1.9 Hz), 138.6 (d, J = 1.2 Hz), 132.9, 131.3, 129.4, 127.7, 127.6 (d, J = 7.6 Hz), 123.6, 116.3 (d, J = 29.8 Hz), 116.2, 115.4 (d, J = 22.1 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -126.86. IR (KBr): 3459, 3375, 3059, 2922, 1617, 1500, 1423, 1265, 752 cm⁻¹. HRMS (ESI) m/z calculated for C₁₂H₉BrFNNa [M+Na]⁺ 287.9800, found 287.9796.



2'-Bromo-5-(trifluoromethyl)-[1,1'-biphenyl]-2-amine (1h)

Compound **1h** was prepared from 2-iodo-4-(trifluoromethyl)aniline by using Method A.

1h (Red oil, 0.62 g, 78% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.69 (d, J = 8.0 Hz, 1H), 7.40 (dd, J = 15.2, 7.7 Hz, 2H), 7.32 – 7.22 (m, 3H), 6.77 (d, J = 8.4 Hz, 1H), 3.83 (s, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 146.7, 138.5, 133.4, 131.8, 129.9, 128.1, 127.7 (q, J = 3.8 Hz), 126.3 (q, J = 3.8 Hz), 126.2, 124.8 (q, J = 270.5 Hz) 124.1, 119.9 (q, J = 32.5 Hz), 114.8. ¹⁹F NMR (376 MHz, CDCl₃): δ -60.94. IR (KBr): 3484, 3398, 3060, 2924, 1623, 1512, 1331, 1270, 751 cm⁻¹. HRMS (ESI) m/z calculated for C₁₃H₉BrF₃NNa [M+Na]⁺ 337.9768, found 337.9754.



2'-Bromo-5-(trifluoromethoxy)-[1,1'-biphenyl]-2-amine (1i)

Compound	1i	was	prepared	from

2-(4,4,5,5-tetramethyl-1,3,2-dioxabrolan-2-yl)-4-(trifluromethoxy)aniline by using Method B.

1i (Colorless oil, 0.55 g, 55% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.70 (d, J = 8.0 Hz, 1H), 7.39 (t, J = 7.4 Hz, 1H), 7.31 (dd, J = 7.6, 1.5 Hz, 1H), 7.29 – 7.23 (m, 1H), 7.06 (d, J = 8.7 Hz, 1H), 6.93 (s, 1H), 6.72 (d, J = 8.7 Hz, 1H), 3.57 (s, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 142.6, 140.9, 140.8, 138.6, 133.3, 131.6, 129.8, 128.0, 127.4, 124.0, 123.4, 120.7 (q, J = 255.9 Hz), 115.9. ¹⁹F NMR (376 MHz, CDCl₃): δ -58.35. IR (KBr): 3475, 3388, 3060, 2924, 1619, 1471, 1256, 754 cm⁻¹. HRMS (ESI) m/z calculated for C₁₃H₁₀BrF₃NO [M+H]⁺ 331.9898, found 331.9892.



2'-Bromo-6-methyl-[1,1'-biphenyl]-2-amine (1j)

Compound **1j** was prepared from 3-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) aniline by using Method B.

1j (White solid, 0.64 g, 81% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.69 – 7.63 (m, 1H), 7.34 (td, J = 7.6, 1.2 Hz, 1H), 7.19 – 7.15 (m, 2H), 7.04 (t, J = 7.8 Hz, 1H), 6.65 (d, J = 7.5 Hz, 1H), 6.58 (d, J = 8.0 Hz, 1H), 3.25 (s, 2H), 1.88 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 143.4, 139.0, 137.0, 133.3, 131.7, 129.3, 128.6, 128.3, 127.1, 124.9, 120.0, 113.0, 20.2. IR (KBr): 3465, 3375, 3056, 2960, 1613, 1462, 1301, 767 cm⁻¹. HRMS (ESI) m/z calculated for C₁₃H₁₂BrNNa [M+Na]⁺ 284.0051, found 284.0048.



2'-Bromo-3,5-dimethyl-[1,1'-biphenyl]-2-amine (1k)

Compound 1k was prepared from 2-iodo-4,6-dimethylaniline by using Method A.

1k (White solid, 0.46 g, 66% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.66 (dd, J = 8.0, 3.0 Hz, 1H), 7.39 – 7.32 (m, 1H), 7.32 – 7.27 (m, 1H), 7.24 – 7.16 (m, 1H), 6.93 (s, 1H), 6.72 (d, J = 2.9 Hz, 1H), 3.32 (s, 2H), 2.24 (s, 3H), 2.18 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 140.5, 139.3, 133.1, 132.0, 131.1, 129.2, 128.4, 127.9, 127.1, 127.0, 124.3, 122.7, 20.5, 17.9. IR (KBr): 3463, 3379, 3009, 2918, 1615, 1475, 1260, 753 cm⁻¹. HRMS (ESI) m/z calculated for C₁₄H₁₅BrN [M+H]⁺ 276.0388, found 276.0381.



2'-Bromo-5-(tert-butyl)-4'-methoxy-[1,1'-biphenyl]-2-amine (11)

Compound 11 was prepared from 2-bromo-1-iodo-4-methoxybenzene by using Method B.

11 (Red solid, 0.49 g, 49% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.26 (t, *J* = 5.6 Hz, 2H), 7.21 (dd, *J* = 8.3, 2.3 Hz, 1H), 7.04 (d, *J* = 2.2 Hz, 1H), 6.94 (dd, *J* = 8.5, 2.5 Hz, 1H), 6.72 (d, *J* = 8.3 Hz, 1H), 3.84 (s, 3H), 3.44 (s, 2H), 1.29 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 159.5, 141.3, 141.1, 132.5, 132.2, 127.9, 126.4, 125.7, 124.6, 118.2, 115.1, 113.9, 55.6, 34.0, 31.6. IR (KBr): 3454, 3377, 3009, 2956, 1606, 1491, 1221, 752 cm⁻¹. HRMS (ESI) m/z calculated for C₁₇H₂₀BrNNaO [M+Na]⁺ 356.0626, found 356.0624.



2'-Bromo-5-(tert-butyl)-4'-fluoro-[1,1'-biphenyl]-2-amine (1m)

Compound 1m was prepared from 2-bromo-4-fluoro-1-iodobenzene by using Method B.

1m (Red oil, 0.56 g, 58% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.45 (dd, J = 8.3, 2.6 Hz, 1H), 7.33 (dd, J = 8.5, 6.1 Hz, 1H), 7.24 (dd, J = 8.2, 2.2 Hz, 1H), 7.11 (td, J = 8.3, 2.6 Hz, 1H), 7.01 (d, J = 2.3 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 3.42 (s, 2H), 1.29 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 161.8 (d, J = 250.8 Hz), 141.2, 141.1, 136.5 (d, J = 3.6 Hz), 132.7 (d, J = 8.3 Hz), 127.6, 126.1, 125.7, 124.6 (d, J = 9.5 Hz), 120.3 (d, J = 24.2 Hz), 115.3, 115.0 (d, J = 20.9 Hz), 34.0, 31.5. ¹⁹F NMR (376 MHz, CDCl₃): δ -112.76. IR (KBr): 3455, 3062, 2958, 1609, 1480, 1259, 753 cm⁻¹. HRMS (ESI) m/z calculated for C₁₆H₁₇BrFNNa [M+Na]⁺ 344.0426, found 344.0416.



2'-Bromo-5-(tert-butyl)-4'-chloro-[1,1'-biphenyl]-2-amine (1n)

Compound **1n** was prepared from 2-bromo-4-chloro-1-iodobenzene by using Method B.

1n (Red oil, 0.65 g, 64% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.71 (d, J = 1.5 Hz, 1H), 7.35 (dd, J = 8.2, 1.4 Hz, 1H), 7.29 (d, J = 8.2 Hz, 1H), 7.23 (dd, J = 8.4, 2.0 Hz, 1H), 7.01 (d, J = 2.0 Hz, 1H), 6.71 (d, J = 8.4 Hz, 1H), 3.40 (s, 2H), 1.29 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 141.1, 140.8, 138.9, 133.9, 132.7, 132.5, 127.9, 127.2, 126.1, 125.3, 124.7, 115.3, 33.9, 31.4. IR (KBr): 3460, 3374, 2961, 1620, 1502, 1468, 872, 819, 766 cm⁻¹. HRMS (ESI) m/z calculated for C₁₆H₁₇BrClNNa [M+Na]⁺ 360.0131, found 360.0120.



2'-Bromo-5-(tert-butyl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-2-amine (10)

Compound **10** was prepared from 2-bromo-1-iodo-4-(trifluoromethyl)benzene by using Method B. **10** (White solid, 0.64 g, 57% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.97 (s, 1H), 7.65 (dd, *J* = 8.0, 1.1 Hz, 1H), 7.50 (d, *J* = 7.9 Hz, 1H), 7.27 (dd, *J* = 8.3, 2.5 Hz, 1H), 7.02 (d, *J* = 2.3 Hz, 1H), 6.75 (d, *J* = 8.4 Hz, 1H), 3.43 (s, 2H), 1.30 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 144.5, 141.4, 140.7, 132.3, 131.3 (q, *J* = 33.1 Hz), 130.2 (q, *J* = 3.9 Hz), 127.0, 126.5, 125.3, 124.8, 124.6 (q, *J* = 3.5 Hz), 120.5 (q, *J* = 272.6 Hz), 115.6, 34.0, 31.5. ¹⁹F NMR (376 MHz, CDCl₃): δ -62.65. IR (KBr): 3462, 3383, 3053, 2959, 1618, 1383, 1264, 743 cm⁻¹. HRMS (ESI) m/z calculated for C₁₇H₁₇BrF₃NNa [M+Na]⁺ 394.0394, found 394.0394.



2'-Bromo-5-(*tert*-butyl)-4'-(trifluoromethoxy)-[1,1'-biphenyl]-2-amine (1p)

Compound 1p was prepared from 2-bromo-1-iodo-4-(trifluoromethyl)benzene by using Method B.

1p (White solid, 0.80 g, 69% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J = 1.4 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.27 – 7.23 (m, 2H), 7.02 (d, J = 2.3 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 3.42 (s, 2H), 1.29 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 148.6, 141.3, 140.9, 139.4, 132.7, 127.4, 126.3, 125.7, 125.3, 124.7, 120.4 (q, J = 258.5 Hz), 120.3, 115.5, 34.0, 31.5. ¹⁹F NMR (376 MHz, CDCl₃): δ -57.84. IR (KBr): 3461, 3375, 3058, 2960, 1618, 1478, 1399, 1370, 1265, 744 cm⁻¹. HRMS (ESI) m/z calculated for C₁₇H₁₈BrF₃NO [M+H]⁺ 388.0524, found 388.0524.



Ethyl 2'-amino-2-bromo-5'-(tert-butyl)-[1,1'-biphenyl]-4-carboxylate (1q)

Compound 1q was prepared from ethyl 3-bromo-4-iodobenzoate by using Method B.

1q (Brown solid, 0.50 g, 44% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.37 (d, J = 1.2 Hz, 1H), 8.05 (dd, J = 7.9, 1.4 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.25 (dd, J = 7.9, 2.7 Hz, 1H), 7.03 (d, J = 2.2 Hz, 1H), 6.74 (d, J = 8.4 Hz, 1H), 4.42 (q, J = 7.1 Hz, 2H), 3.43 (s, 2H), 1.42 (t, J = 7.1 Hz, 3H), 1.30 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 165.2, 145.2, 141.2, 140.7, 134.3, 131.9, 131.3, 128.8, 127.0, 126.4, 125.8, 124.4, 115.5, 61.5, 34.0, 31.5, 14.4. IR (KBr): 3462, 3376, 2959, 1717, 1619, 1472, 1373, 1267, 869 cm⁻¹. HRMS (ESI) m/z calculated for C₁₉H₂₂BrNNaO₂ [M+Na]⁺ 398.0732, found 398.0714.



2'-Amino-2-bromo-5'-(*tert*-butyl)-[1,1'-biphenyl]-4-carbonitrile (1r)

Compound 1r was prepared from 3-bromo-4-iodobenzonitrile by using Method B.

1r (White solid, 0.52 g, 53% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.00 (d, J = 1.5 Hz, 1H), 7.68 (dd, J = 7.9, 1.6 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.27 (dd, J = 8.3, 2.2 Hz, 1H), 6.99 (d, J = 2.3 Hz, 1H), 6.75 (d, J = 8.4 Hz, 1H), 3.42 (s, 2H), 1.29 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 145.9, 141.5, 140.5, 136.5, 132.6, 131.2, 126.9, 126.8, 125.0, 124.9, 117.3, 115.8, 112.9, 38.3, 31.8. IR (KBr): 3456, 3377, 3054, 2959, 2232, 1623, 1501, 1437, 1264, 754 cm⁻¹. HRMS (ESI) m/z calculated for C₁₇H₁₇BrN₂Na [M+Na]⁺ 351.0473, found 351.0461.



2'-Bromo-5-(tert-butyl)-4'-nitro-[1,1'-biphenyl]-2-amine (1s)

Compound 1s was prepared from 2-bromo-1-iodo-4-nitrobenzene by using Method B.

1s (Yellow solid, 0.62 g, 59% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.58 (d, J = 2.3 Hz, 1H), 8.24 (dd, J = 8.4, 2.3 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.28 (dd, J = 8.4, 2.3 Hz, 1H), 7.01 (d, J = 2.3 Hz, 1H), 6.76 (d, J = 8.4 Hz, 1H), 3.44 (s, 2H), 1.30 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 147.6, 147.5, 141.5, 140.5, 132.5, 128.4, 127.0, 126.8, 124.9, 124.6, 122.6, 115.8, 34.1, 31.5. IR (KBr): 3446, 3367, 3105, 2954, 1626, 1512, 1349, 1267, 751 cm⁻¹. HRMS (ESI) m/z calculated for C₁₆H₁₇BrN₂NaO₂ [M+Na]⁺ 371.0371, found 371.0361.



2'-Bromo-5-(tert-butyl)-5'-fluoro-[1,1'-biphenyl]-2-amine (1t)

Compound 1t was prepared from 1-bromo-4-fluoro-2-iodobenzene by using Method B.

It (Red oil, 0.77 g, 80% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.64 (dd, J = 8.8, 5.4 Hz, 1H), 7.27 – 7.21 (m, 1H), 7.10 (dd, J = 8.9, 3.1 Hz, 1H), 7.02 (d, J = 2.3 Hz, 1H), 6.99 – 6.94 (m, 1H), 6.73 (d, J = 8.4 Hz, 1H), 3.45 (s, 2H), 1.29 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 162.0 (d, J = 248.4 Hz), 142.4 (d, J = 7.9 Hz), 141.3, 140.7, 134.4 (d, J = 8.3 Hz), 127.1, 126.3, 125.7 (d, J = 1.3 Hz), 118.9 (d, J = 22.1 Hz), 118.6 (d, J = 3.2 Hz), 116.3 (d, J = 22.3 Hz), 115.5, 34.0, 31.5. ¹⁹F NMR (376 MHz, CDCl₃): δ -114.48. IR (KBr): 3446, 3051, 2970, 1617, 1461, 1266, 760 cm⁻¹. HRMS (ESI) m/z calculated for C₁₆H₁₈BrFN [M+H]⁺ 322.0607, found 322.0606.



2'-Bromo-5-(tert-butyl)-6'-chloro-[1,1'-biphenyl]-2-amine (1u)

Compound 1u was prepared from 2-bromo-3-chlore-2-iodobenzene by using Method B.

1u (Red oil, 0.63 g, 62% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.58 (d, J = 8.0 Hz, 1H), 7.42 (t, J = 9.0 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.11 (t, J = 8.0 Hz, 1H), 6.97 (s, 1H), 6.72 (d, J = 8.4 Hz, 1H), 3.34 (s, 2H), 1.29 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 141.4, 140.9, 139.2, 135.9, 131.7, 130.0, 129.1, 127.2, 126.4, 126.3, 124.8, 115.6, 34.2, 31.7. IR (KBr): 3460, 3375, 3037, 2960, 1621, 1425, 1291, 765 cm⁻¹. HRMS (ESI) m/z calculated for C₁₆H₁₈BrClN [M+H]⁺ 338.0311, found 338.0310.

C. Preparation of the enamines 3:

(I) Optimization of the reaction conditions for the preparation of 3a:

2'-Bromo-[1,1'-biphenyl]-2-amine (1a) and diphenylacetylene (2a) were chosen as the model substrates to optimize the reaction conditions for the synthesis of enamine 3a. Several solvents, ligands, palladium sources and bases were surveyed. The optimization details are shown in Table S1, and the optimized reaction conditions were obtained as the following: 10 mol % of Pd(OAc)₂, 12 mol % of DPPM and 2.0 equivalents of K_2CO_3 in THF at 100 °C for 16 h.

Table S1. Optimization of the reaction conditions for the synthesis of enamine 3a.^a



entry	[Pd]	ligand	base	solvent	yield (%) ^b			
chu y	լլայ	inganu			3a	4 a		
1	$Pd(OAc)_2$	PPh ₃	K_2CO_3	DMF	61	19		
2	$Pd(OAc)_2$	PPh ₃	K_2CO_3	DMSO	0	13		
3	$Pd(OAc)_2$	PPh ₃	K_2CO_3	THF	74	trace		
4	$Pd(OAc)_2$	—	K_2CO_3	THF	0	0		
5	$Pd(OAc)_2$	PCy ₃	K_2CO_3	THF	0	0		
6	$Pd(OAc)_2$	Xphos	K_2CO_3	THF	45	trace		
7	Pd(OAc) ₂	DPPM	K ₂ CO ₃	THF	92	trace		
8	$Pd(OAc)_2$	DPPE	K_2CO_3	THF	42	trace		
9	$Pd(OAc)_2$	DPPP	K_2CO_3	THF	86	trace		
10	$Pd(OAc)_2$	DPPF	K_2CO_3	THF	71	trace		
11	$Pd(OAc)_2$	BINAP	K_2CO_3	THF	68	trace		
12	$Pd(OAc)_2$	Xantphos	K_2CO_3	THF	84	trace		
13	PdCl ₂	DPPM	K_2CO_3	THF	8	0		
14	[Pd(allyl)Cl] ₂	DPPM	K_2CO_3	THF	0	0		
15	$Pd_2(dba)_3$	DPPM	K_2CO_3	THF	0	0		
16	$Pd(OAc)_2$	DPPM	Na_2CO_3	THF	59	trace		
17	$Pd(OAc)_2$	DPPM	Cs_2CO_3	THF	0	13		
18	$Pd(OAc)_2$	DPPM	K_3PO_4	THF	0	30		
^a 0.2 mmol scale. ^b Isolated yield.								

(II) General procedure for the preparation of enamines 3:



In a glovebox, a 25.0 mL vial equipped with a stir bar was charged with $Pd(OAc)_2$ (22.4 mg, 0.1 mmol), DPPM (46.1 mg, 0.12 mmol) and THF (5.0 mL) was then added. After the catalyst mixture was stirred at room temperature for 10 min, **1** (1.0 mmol), **2** (1.5 mmol) and K₂CO₃ (276.4 mg, 2.0 mmol) were sequentially added. The vial was sealed with a Teflon screw cap and the reaction mixture was heated at 100 °C for 16 h. After the reaction vessel was cooled to room temperature, the mixture was concentrated under reduced pressure. The residue was then quickly chromatographed on basic alumina (petroleum ether/THF) to afford the desired product **3**.



6,7-Diphenyl-5*H*-dibenzo[*b*,*d*]azepine (3a)

Yellow solid (317.4 mg, 92% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.55 – 7.51 (m, 1H), 7.44 (d, *J* = 6.9 Hz, 1H), 7.28 (dd, *J* = 7.4, 1.0 Hz, 1H), 7.22 – 7.11 (m, 8H), 7.09 – 7.06 (m, 3H), 7.03 – 7.98 (m,

2H), 6.89 (dd, J = 7.9, 0.9 Hz, 1H), 6.60 (dd, J = 5.7, 3.4 Hz, 1H), 4.76 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 152.3, 148.0, 141.1, 140.9, 140.7, 140.0, 133.3, 131.7, 130.4, 130.2, 129.7, 128.3, 128.2, 128.1, 127.6, 127.4, 127.0, 126.9, 126.1, 125.8, 124.2, 119.8. IR (KBr): 3366, 3055, 1641, 1593, 1477, 1261, 739 cm⁻¹. HRMS (ESI) m/z calculated for C₂₆H₂₀N [M+H]⁺ 346.1596, found 346.1596.



2-Methyl-6,7-diphenyl-5*H*-dibenzo[*b*,*d*]azepine (3b)

Yellow solid (266.0 mg, 74% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.47 (d, J = 7.2 Hz, 1H), 7.35 (s, 1H), 7.29 (dd, J = 9.6, 2.3 Hz, 1H), 7.23 – 7.11 (m, 6H), 7.09 (dd, J = 5.1, 1.6 Hz, 3H), 7.03 – 6.97 (m, 3H), 6.90 (d, J = 7.9 Hz, 1H), 6.52 (d, J = 7.9 Hz, 1H), 4.72 (s, 1H), 2.40 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 149.8, 148.3, 141.2, 140.9, 140.7, 140.0, 133.5, 133.1, 131.7, 130.7, 130.4, 129.6, 128.7, 128.3, 128.1, 127.6, 127.3, 126.9, 126.8, 126.1, 125.6, 119.6, 20.9. IR (KBr): 3373, 3053, 2924, 1604, 1456, 1264, 739 cm⁻¹. HRMS (ESI) m/z calculated for C₂₇H₂₂N [M+H]⁺ 360.1752, found 360.1758.



2-Isopropyl-6,7-diphenyl-5*H*-dibenzo[*b*,*d*]azepine (3c)

Yellow solid (243.8 mg, 63% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.47 (d, *J* = 7.8 Hz, 1H), 7.38 (s, 1H), 7.29 (d, *J* = 7.5 Hz, 1H), 7.18 – 7.13 (m, 6H), 7.11 – 7.08 (m, 3H), 7.03 (t, *J* = 5.5 Hz, 3H), 6.90 (d, *J* = 7.9 Hz, 1H), 6.54 (d, *J* = 8.0 Hz, 1H), 4.73 (s, 1H), 2.96 (dt, *J* = 13.6, 6.8 Hz, 1H), 1.32 (d, *J* = 6.9 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 149.9, 148.3, 144.5, 141.2, 140.9, 140.8, 140.3, 133.0, 131.8, 130.4, 129.6, 128.3, 128.2, 128.1, 127.5, 127.3, 126.9, 126.8, 126.1, 126.0, 125.4, 119.6, 33.6, 24.2. IR (KBr): 3437, 3058, 2959, 1635, 1431, 1325, 1255, 736 cm⁻¹. HRMS (ESI) m/z calculated for C₂₉H₂₆N [M+H]⁺ 388.2065, found 388.2065.



2-(Tert -butyl)-6,7-diphenyl-5H-dibenzo[b,d]azepine (3d)

Yellow solid (337.7 mg, 84% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.54 (d, *J* = 1.9 Hz, 1H), 7.47 (d, *J* = 7.8 Hz, 1H), 7.29 (t, *J* = 7.6 Hz, 1H), 7.23 – 7.13 (m, 7H), 7.13 – 7.07 (m, 3H), 7.07 – 7.01 (m, 2H), 6.90 (d, *J* = 7.9 Hz, 1H), 6.54 (d, *J* = 8.2 Hz, 1H), 4.74 (s, 1H), 1.40 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 149.7, 148.2, 146.7, 141.2, 141.0, 140.7, 140.5, 132.5, 131.7, 130.3, 129.6, 128.2, 128.1, 127.5, 127.3, 127.2, 126.9, 126.7, 126.0, 125.3, 124.9, 119.2, 34.4, 31.5. IR (KBr): 3372, 3055, 2960, 1601, 1494, 1263, 737 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₇NNa [M+Na]⁺ 424.2041, found 424.2020.



2,6,7-Triphenyl-6,7-diphenyl-5*H*-dibenzo[*b*,*d*]azepine (3e)

Yellow solid (227.3 mg, 54% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.67 (d, J = 2.0 Hz, 1H), 7.59 – 7.54 (m, 1H), 7.43 (d, J = 6.8 Hz, 1H), 7.38 (t, J = 7.6 Hz, 2H), 7.32 (dd, J = 8.1, 2.1 Hz, 1H), 7.28 (d, J = 7.3 Hz, 1H), 7.22 (dd, J = 7.5, 1.1 Hz, 1H), 7.13 – 7.06 (m, 7H), 7.04 – 7.00 (m, 3H), 6.98 – 6.93 (m, 2H), 6.84 (d, J = 7.9 Hz, 1H), 6.60 (d, J = 8.1 Hz, 1H), 4.76 (s, 1H). ¹³C NMR: (100 MHz, CDCl₃): δ 151.7, 148.0, 141.1, 141.0, 140.8, 140.7, 139.9, 137.2, 133.5, 131.7, 130.4, 129.8, 129.0, 128.8, 128.4, 128.1, 127.6, 127.4, 127.2, 127.1, 127.0, 126.8, 126.7, 126.2, 125.7, 120.1. IR (KBr): 3370, 3023, 2970, 1603, 1265, 754 cm⁻¹. HRMS (ESI) m/z calculated for C₃₂H₂₄N [M+H]⁺ 422.1909, found 422.1900.



2-Methoxy-6,7-diphenyl-5*H*-dibenzo[*b*,*d*]azepine (3f)

Yellow solid (228.8 mg, 61% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.49 (dd, J = 7.8, 1.1 Hz, 1H), 7.29 (td, J = 7.7, 1.3 Hz, 1H), 7.21 – 7.13 (m, 6H), 7.09 (dd, J = 6.6, 2.3 Hz, 4H), 7.00 (dd, J = 7.0, 2.7 Hz, 2H), 6.92 (dd, J = 7.9, 1.0 Hz, 1H), 6.74 (dd, J = 8.5, 2.9 Hz, 1H), 6.55 (d, J = 8.5 Hz, 1H), 4.63 (s, 1H), 3.86 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 156.6, 148.6, 145.5, 141.1, 141.0, 140.6, 139.8, 134.4, 131.7, 130.5, 129.4, 128.3, 128.1, 127.6, 127.3, 127.0, 126.9, 126.1, 125.6, 120.5, 115.3, 113.3, 55.7. IR (KBr): 3444, 3031, 2924, 2856, 1622, 1459, 1263, 749 cm⁻¹. HRMS (ESI) m/z calculated for C₂₇H₂₂NO [M+H]⁺ 376.1701, found 376.1669.



2-Fluoro-6,7-diphenyl-5*H*-dibenzo[*b*,*d*]azepine (3g)

Yellow solid (250.5 mg, 69% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.43 (dd, J = 7.8, 0.9 Hz, 1H), 7.30 (td, J = 7.7, 1.1 Hz, 1H), 7.25 – 7.16 (m, 5H), 7.15 – 7.11 (m, 2H), 7.09 (dd, J = 5.0, 1.8 Hz, 3H), 6.99 (dd, J = 6.6, 3.0 Hz, 2H), 6.92 (d, J = 6.9 Hz, 1H), 6.87 (td, J = 8.3, 2.9 Hz, 1H), 6.55 (dd, J = 8.6, 4.9 Hz, 1H), 4.69 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 160.0 (d, J = 240.7 Hz), 148.1, 148.0, 147.9, 140.9 (d, J = 2.5 Hz), 140.4, 138.9, 134.9 (d, J = 7.7 Hz), 131.7, 130.5, 129.5, 128.4, 128.1, 127.7, 127.5, 127.4, 127.2, 126.3, 126.0, 120.6 (d, J = 8.3 Hz), 116.3 (d, J = 23.2 Hz), 114.4 (d, J = 22.6 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -120.43. IR (KBr): 3369, 3057, 2923, 1638, 1599, 1258, 766 cm⁻¹. HRMS (ESI) m/z calculated for C₂₆H₁₉FN [M+H]⁺ 364.1502, found 364.1500.



6,7-Diphenyl-2-(trifluoromethyl)-5*H*-dibenzo[*b*,*d*]azepine (3h)

Yellow solid (335.3 mg, 81% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.78 (s, 1H), 7.42 (d, *J* = 7.8 Hz, 2H), 7.36 – 7.29 (m, 1H), 7.23 – 7.18 (m, 4H), 7.16 – 7.09 (m, 5H), 7.04 – 7.00 (m, 2H), 6.92 (d, *J* = 7.9 Hz, 1H), 6.67 (d, *J* = 8.2 Hz, 1H), 4.93 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 155.5, 147.2, 140.9, 140.6, 140.3, 138.7, 133.5, 131.6, 130.6, 129.9, 128.5, 128.1, 127.8, 127.7, 127.6, 127.5, 127.3 (q, *J* = 3.8 Hz), 126.4, 126.3, 126.2 (q, *J* = 32.4 Hz), 125.1 (q, *J* = 3.7 Hz), 124.5 (q, *J* = 271.7 Hz), 119.7. ¹⁹F NMR (376 MHz, CDCl₃): δ -61.69. IR (KBr): 3366, 3059, 2925, 1606, 1484, 1260, 737 cm⁻¹. HRMS (ESI) m/z calculated for C₂₇H₁₈F₃NNa [M+Na]⁺ 436.1289, found 436.1274.



6,7-Diphenyl-2-(trifluoromethoxy)-5H-dibenzo[b,d]azepine (3i)

Yellow solid (343.6 mg, 80% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.43 – 7.37 (m, 2H), 7.31 (t, J = 7.5 Hz, 1H), 7.22 – 7.07 (m, 9H), 7.06 – 6.99 (m, 3H), 6.92 (dd, J = 7.8, 3.7 Hz, 1H), 6.59 (d, J = 8.5 Hz, 1H), 4.78 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 150.8, 147.8, 145.9, 145.8, 140.9, 140.7, 140.3, 138.6, 134.6, 131.6, 130.5, 129.6, 128.4, 128.1, 127.7, 127.6, 127.3, 126.3, 126.0, 122.7, 120.7 (q, J = 256.8 Hz), 120.6, 120.4. ¹⁹F NMR (376 MHz, CDCl₃): δ -57.96. IR (KBr): 3436, 3064, 2960, 1637, 1474, 1256, 743 cm⁻¹. HRMS (ESI) m/z calculated for C₂₇H₁₈F₃NNaO [M+Na]⁺ 452.1238, found 452.1210.



1-Methyl-6,7-diphenyl-5*H*-dibenzo[*b*,*d*]azepine (3j)

Yellow solid (212.2 mg, 59% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.37 (d, J = 7.2 Hz, 1H), 7.28 – 7.23 (m, 2H), 7.22 – 7.15 (m, 4H), 7.14 – 7.09 (m, 5H), 7.07 (d, J = 4.7 Hz, 1H), 7.05 – 7.00 (m, 2H), 6.98 (d, J = 7.8 Hz, 1H), 6.49 (d, J = 7.0 Hz, 1H), 4.71 (s, 1H), 2.46 (s, 3H).¹³C NMR (100 MHz, CDCl₃): δ 154.5, 148.2, 141.9, 140.6, 140.4, 138.9, 137.5, 132.2, 131.6, 131.2, 129.8, 128.4, 128.1, 127.6, 127.4, 127.1, 127.0, 126.5, 126.3, 126.2, 125.7, 117.5, 21.6. IR (KBr): 3361, 3056, 2923, 1656, 1463, 1265, 735 cm⁻¹. HRMS (ESI) m/z calculated for C₂₇H₂₂N [M+H]⁺ 360.1752, found 360.1752.



2,4-Dimethyl-6,7-diphenyl-5*H*-dibenzo[*b*,*d*]azepine (3k)

Yellow solid (340.0 mg, 91% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.48 (d, *J* = 7.7 Hz, 1H), 7.30 (d, *J* = 7.3 Hz, 1H), 7.21 – 7.13 (m, 7H), 7.11 – 7.07 (m, 3H), 7.00 (dd, *J* = 6.5, 2.9 Hz, 2H), 6.92 – 6.87 (m, 2H), 4.84 (s, 1H), 2.36 (s, 3H), 1.90 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 148.5, 147.8, 141.2, 141.0, 140.9, 140.6, 133.5, 132.8, 131.7, 130.3, 130.2, 129.7, 128.7, 128.4, 127.7, 127.6, 127.2, 126.9, 126.6, 126.5, 126.1, 20.8, 17.4. IR (KBr): 3438, 3059, 2924, 1615, 1429, 1256, 737 cm⁻¹. HRMS (ESI) m/z calculated for C₂₈H₂₄N [M+H]⁺ 374.1909, found 374.1905.



2-(*Tert*-butyl)-9-methoxy-6,7-diphenyl-5*H*-dibenzo[*b*,*d*]azepine (3l)

Yellow solid (207.2 mg, 48% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.50 – 7.47 (m, 1H), 7.40 (d, J = 8.6 Hz, 1H), 7.20 – 7.13 (m, 6H), 7.11 – 7.06 (m, 3H), 7.06 – 7.01 (m, 2H), 6.87 (dd, J = 8.6, 2.6 Hz, 1H), 6.53 (d, J = 8.2 Hz, 1H), 6.45 (d, J = 2.6 Hz, 1H), 4.75 (s, 1H), 3.65 (s, 3H), 1.39 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 158.3, 148.9, 148.2, 146.7, 142.2, 141.0, 140.8, 133.2, 132.3, 131.7, 130.8, 128.3, 128.1, 127.6, 127.3, 126.8, 126.1, 125.1, 124.4, 119.1, 115.7, 113.0, 55.2, 34.4, 31.6. IR (KBr): 3434, 3053, 2925, 1615, 1455, 1398, 1267, 753 cm⁻¹. HRMS (ESI) m/z calculated for C₃₁H₂₉NNaO [M+Na]⁺ 454.2147, found 454.2140.



2-(Tert-butyl)-9-fluoro-6,7-diphenyl-5H-dibenzo[b,d]azepine (3m)

Yellow solid (310.2 mg, 74% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.50 (d, J = 1.7 Hz, 1H), 7.44 (dd, J = 8.5, 6.1 Hz, 1H), 7.25 – 7.16 (m, 6H), 7.15 – 7.09 (m, 3H), 7.07 – 6.99 (m, 3H), 6.63 (dd, J = 10.9, 2.5 Hz, 1H), 6.56 (d, J = 8.2 Hz, 1H), 4.80 (s, 1H), 1.42 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 161.8 (d, J = 244.0 Hz), 149.3, 149.2, 147.0, 143.2 (d, J = 7.4 Hz), 140.6, 140.5, 136.6 (d, J = 2.7 Hz), 131.7, 131.4, 131.3, 128.4, 128.1, 127.8, 127.5, 127.1, 126.4, 125.1, 124.4, 119.4, 116.7 (d, J = 22.0 Hz), 144.1 (d, J = 22.0 Hz), 34.5, 31.6. ¹⁹F NMR (376 MHz, CDCl₃): δ -116.13. IR (KBr): 3370, 3054, 2960, 1491, 1261, 754 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₇FN [M+H]⁺ 420.2128, found 420.2120.



2-(*Tert*-butyl)-9-fluoro-6,7-diphenyl-5*H*-dibenzo[*b*,*d*]azepine (3n)

Yellow solid (292.2 mg, 67% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.46 (d, J = 2.2 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.24 (dd, J = 8.4, 2.2 Hz, 1H), 7.21 – 7.16 (m, 4H), 7.15 – 7.07 (m, 5H), 7.00 (dd, J = 6.7, 2.8 Hz, 2H), 6.86 (d, J = 2.2 Hz, 1H), 6.53 (d, J = 8.2 Hz, 1H), 4.75 (s, 1H), 1.38 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 149.5, 147.1, 142.8, 140.5, 140.4, 139.0, 132.9, 131.7, 131.6, 131.0, 130.0, 128.4, 128.0, 127.8, 127.5, 127.0, 126.4, 125.4, 124.2, 119.4, 34.4, 31.6. IR (KBr): 3372, 3056, 2960, 1640, 1593, 1482, 1261, 749 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₇ClN [M+H]⁺ 436.1832, found 436.1813.



2-(*Tert*-butyl-6,7-diphenyl-9-(trifluoromethyl)-5*H*-dibenzo[*b*,*d*]azepine (30)

Yellow solid (249.1 mg, 53% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.56 (d, *J* = 8.2 Hz, 1H), 7.53 (d, *J* = 2.2 Hz, 2H), 7.28 – 7.23 (m, 1H), 7.22 – 7.19 (m, 3H), 7.19 – 7.15 (m, 3H), 7.12 (dd, *J* = 6.9, 3.6 Hz, 3H), 7.03 (dd, *J* = 6.6, 2.9 Hz, 2H), 6.57 (d, *J* = 8.2 Hz, 1H), 4.79 (s, 1H), 1.41 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 150.1, 149.9, 147.3, 144.1, 141.8, 140.5, 140.2, 131.7, 131.4, 130.1, 128.8 (q, *J* = 32.3 Hz), 128.4, 128.0, 127.8, 127.6, 127.3, 127.0 (q, *J* = 3.8 Hz), 126.6, 126.0, 124.4, 124.2 (q, *J* = 272.4 Hz), 123.3 (q, *J* = 4.0 Hz), 119.6, 34.5, 31.5. ¹⁹F NMR (376 MHz, CDCl₃): δ -62.69. IR (KBr): 3367, 3056, 2961, 1605, 1495, 1331, 1260, 747 cm⁻¹. HRMS (ESI) m/z calculated for C₃₁H₂₆F₃NNa [M+Na]⁺ 492.1915, found 492.1912.



2-(*Tert*-butyl-6,7-diphenyl-9-(trifluoromethoxy)-5*H*-dibenzo[*b*,*d*]azepine (3p)

Yellow solid (329.8 mg, 68% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.48 – 7.43 (m, 2H), 7.23 – 7.12 (m, 7H), 7.10 (dd, *J* = 5.0, 1.9 Hz, 3H), 7.00 (dd, *J* = 6.6, 3.1 Hz, 2H), 6.71 (d, *J* = 2.1 Hz, 1H), 6.54 (d, *J* = 8.2 Hz, 1H), 4.78 (s, 1H), 1.38 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 149.6, 149.5, 148.1, 147.1, 143.0, 140.5, 140.3, 139.2, 131.6, 131.4, 131.0, 128.4, 128.0, 127.8, 127.6, 127.2, 126.5, 125.5, 124.3, 122.5, 120.4 (q, *J* = 257.0 Hz), 119.5, 119.0, 34.4, 31.5. ¹⁹F NMR (376 MHz, CDCl₃): δ -57.69. IR (KBr): 3433, 3057, 2964, 1663, 1363, 1262, 748 cm⁻¹. HRMS (ESI) m/z calculated for C₃₁H₂₇F₃NO [M+H]⁺ 486.2045, found 486.2043.



Ethyl 2-(*tert*-butyl)-6,7-diphenyl-5*H*-dibenzo[*b*,*d*]azepine-9-carboxylate (3q)

Yellow solid (407.6 mg, 86% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.92 (dd, J = 8.2, 1.7 Hz, 1H), 7.61 (d, J = 1.6 Hz, 1H), 7.53 (d, J = 2.1 Hz, 1H), 7.50 (d, J = 8.2 Hz, 1H), 7.23 (dd, J = 8.2, 2.2 Hz, 1H), 7.21 – 7.14 (m, 5H), 7.13 – 7.07 (m, 3H), 7.07 – 7.01 (m, 2H), 6.56 (d, J = 8.2 Hz, 1H), 4.75 (s, 1H), 4.28 (q, J = 7.1 Hz, 2H), 1.40 (s, 9H), 1.30 (t, J = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 166.5, 150.1, 149.1, 147.0, 145.1, 141.3, 140.6, 140.5, 131.7, 131.5, 129.8, 128.7, 128.3, 128.1, 127.7, 127.5, 127.4, 127.2, 126.4, 125.9, 124.8, 119.5, 60.8, 34.4, 31.5, 14.3. IR (KBr): 3360, 3056, 2962, 1713, 1602, 1459, 1390, 1255, 745 cm⁻¹. HRMS (ESI) m/z calculated for C₃₃H₃₁NNaO₂ [M+Na]⁺ 496.2252, found 496.2247.



2-(*Tert*-butyl)-6,7-diphenyl-5*H*-dibenzo[*b*,*d*]azepine-9-carbonitrile (3r)

Yellow solid (269.0 mg, 63% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.51 (s, 2H), 7.47 (d, J = 2.2 Hz, 1H), 7.26 – 7.23 (m, 1H), 7.22 – 7.18 (m, 3H), 7.18 – 7.08 (m, 6H), 7.04 – 6.97 (m, 2H), 6.55 (d, J = 8.2 Hz, 1H), 4.81 (s, 1H), 1.39 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 150.5, 150.1, 147.4, 145.3, 142.5, 140.2, 139.9, 133.9, 131.6, 130.9, 130.4, 129.6, 128.4, 128.0, 127.9, 127.7, 127.2, 126.8, 126.4, 123.5, 119.7, 119.1, 110.4, 34.5, 31.5. IR (KBr): 3368, 3055, 2961, 2228, 1601, 1265, 753 cm⁻¹. HRMS (ESI) m/z calculated for C₃₁H₂₆N₂Na [M+Na]⁺ 449.1994, found 449.1994.



2-(*Tert*-butyl)-9-nitro-6,7-diphenyl-5*H*-dibenzo[*b*,*d*]azepine (3s)

Yellow solid (307.7 mg, 69% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.08 (dd, J = 8.6, 2.3 Hz, 1H), 7.73 (d, J = 2.3 Hz, 1H), 7.55 (d, J = 8.7 Hz, 1H), 7.52 – 7.48 (m, 1H), 7.33 – 7.28 (m, 1H), 7.23 – 7.18 (m, 3H), 7.17 – 7.10 (m, 5H), 7.07 – 7.00 (m, 2H), 6.59 – 6.56 (d, J = 8.3 Hz, 1H), 4.81 (s, 1H), 1.40 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 150.6, 150.2, 147.5, 147.2, 146.6, 142.7, 140.2, 139.8, 131.6, 130.6, 130.5, 128.4, 128.1, 127.9, 127.8, 127.3, 126.8, 126.7, 125.0, 123.7, 121.2, 119.8, 34.5, 31.5. IR (KBr): 3368, 3059, 2961, 1640, 1515, 1344, 1260, 745 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₆N₂NaO₂ [M+Na]⁺ 469.1892, found 469.1896.



2-(*Tert*-butyl)-10-fluoro-6,7-diphenyl-5*H*-dibenzo[*b*,*d*]azepine (3t)

Yellow solid (301.7 mg, 72% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.49 (d, J = 1.9 Hz, 1H), 7.23 – 7.13 (m, 7H), 7.12 – 7.06 (m, 3H), 7.04 – 6.98 (m, 2H), 6.89 – 6.83 (m, 2H), 6.55 (d, J = 8.2 Hz, 1H), 4.74 (s, 1H), 1.39 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 161.4 (d, J = 246.1 Hz), 149.4, 147.8, 147.0, 142.6 (d, J = 7.5 Hz), 141.1, 140.6, 137.0 (d, J = 2.8 Hz), 132.3 (d, J = 8.3 Hz), 131.7, 128.6 (d, J = 12.6 Hz), 128.3, 128.1, 127.7, 127.4, 127.0, 126.2, 125.7, 124.7, 119.5, 115.7 (d, J = 21.9 Hz), 113.7 (d, J = 21.2 Hz), 34.5, 31.5. ¹⁹F NMR (376 MHz, CDCl₃): δ -115.86. IR (KBr): 3435, 3050, 2958, 1604, 1491, 1265, 755 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₇FN [M+H]⁺ 420.2128, found 420.2125.



2-(*Tert*-butyl)-11-chloro-6,7-diphenyl-5*H*-dibenzo[*b*,*d*]azepine (3u)

Yellow solid (392.4 mg, 90% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.74 (d, J = 2.2 Hz, 1H), 7.39 (dd, J = 7.9, 1.1 Hz, 1H), 7.23 – 7.17 (m, 4H), 7.12 – 7.07 (m, 5H), 7.05 (d, J = 7.9 Hz, 1H), 6.99 (dd, J = 6.5, 3.1 Hz, 2H), 6.84 (dd, J = 8.0, 1.1 Hz, 1H), 6.59 (d, J = 8.2 Hz, 1H), 4.75 (s, 1H), 1.38 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 150.3, 150.0, 145.5, 143.8, 140.6, 140.3, 138.1, 132.4, 131.6, 130.8, 128.7, 128.6, 128.3, 128.2, 127.9, 127.6, 127.4, 127.1, 126.2, 125.0, 124.5, 119.5, 34.4, 31.4. IR (KBr): 3362, 3055, 2961, 1420, 1387, 1262, 738 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₆ClNNa [M+Na]⁺ 458.1651, found 458.1651.



2-(Tert-butyl-6,7-di-p-toyl-5H-dibenzo[b,d]azepine (3a')

Yellow solid (364.7 mg, 85% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.54 (d, *J* = 2.1 Hz, 1H), 7.46 (d, *J* = 7.2 Hz, 1H), 7.31 – 7.27 (m, 1H), 7.19 (dd, *J* = 8.2, 2.2 Hz, 1H), 7.17 – 7.12 (m, 1H), 7.07 (d, *J* = 8.0 Hz, 2H), 7.01 (d, *J* = 8.0 Hz, 2H), 6.94 – 6.87 (m, 5H), 6.54 (d, *J* = 8.2 Hz, 1H), 4.72 (s, 1H), 2.29 (s, 3H), 2.25 (s, 3H), 1.39 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 149.8, 148.0, 146.7, 141.3, 140.5, 138.4, 138.1, 136.9, 135.5, 132.6, 131.6, 130.4, 129.6, 129.0, 128.3, 128.0, 127.2, 126.8, 126.7, 125.1, 125.0, 119.2, 34.5, 31.6, 21.3, 21.2. IR (KBr): 3455, 3020, 2958, 1641, 1501, 1461, 1394, 1265, 754 cm⁻¹. HRMS (ESI) m/z calculated for C₃₂H₃₂N [M+H]⁺ 430.2535, found 430.2526.



2-(Tert-butyl-6,7-bis(4-methoxyphenyl)-5H-dibenzo[b,d]azepine (3b')

Yellow solid (382.6 mg, 83% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.55 (s, 1H), 7.48 (d, *J* = 7.8 Hz, 1H), 7.29 (t, *J* = 7.5 Hz, 1H), 7.22 – 7.14 (m, 2H), 7.12 (d, *J* = 8.4 Hz, 2H), 7.00 – 6.90 (m, 3H), 6.74 (d, *J* = 8.6 Hz, 2H), 6.67 (d, *J* = 8.5 Hz, 2H), 6.56 (d, *J* = 8.2 Hz, 1H), 4.73 (s, 1H), 3.77 (s, 3H), 3.74 (s, 3H), 1.41 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 158.4, 157.7, 149.9, 147.6, 146.7, 141.4, 140.4, 133.9, 133.6, 132.8, 132.6, 130.4, 129.6, 129.5, 127.2, 126.8, 126.7, 125.0, 124.8, 119.2, 113.6, 113.0, 55.2, 55.1, 34.5, 31.6. IR (KBr): 3374, 3055, 2959, 1639, 1504, 1460, 1226, 755 cm⁻¹. HRMS (ESI) m/z calculated for C₃₂H₃₂NO₂ [M+H]⁺ 462.2433, found 462.2427.



2-(*Tert*-butyl-6,7-bis(4-fluorophenyl)-5*H*-dibenzo[*b*,*d*]azepine (3c')

Yellow solid (402.0 mg, 92% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.54 (d, J = 2.0 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.32 (t, J = 7.3 Hz, 1H), 7.22 (dd, J = 8.2, 2.1 Hz, 1H), 7.18 (d, J = 7.3 Hz, 1H), 7.14

(dd, J = 8.5, 5.5 Hz, 2H), 6.99 (dd, J = 8.4, 5.6 Hz, 2H), 6.93 – 6.86 (m, 3H), 6.82 (t, J = 8.7 Hz, 2H), 6.55 (d, J = 8.2 Hz, 1H), 4.67 (s, 1H), 1.41 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 161.7 (d, J = 247.4 Hz), 161.3 (d, J = 245.7 Hz), 149.6, 147.5, 147.1, 140.7, 140.5, 137.1 (d, J = 2.7 Hz), 136.8 (d, J = 3.2 Hz), 133.3 (d, J = 7.9 Hz), 132.5, 130.3, 130.0 (d, J = 8.0 Hz), 129.9, 127.4, 127.2, 126.9, 125.2, 124.8, 119.4, 115.5 (d, J = 21.4 Hz), 114.7 (d, J = 21.2 Hz), 34.5, 31.6. ¹⁹F NMR (376 MHz, CDCl₃): δ -113.28, -115.81. IR (KBr): 3433, 3016, 2960, 1603, 1502, 1395, 1266, 755 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₆F₂N [M+H]⁺ 438.2033, found 438.2032.



6,7-Bis(4-chlorophenyl)-5*H*-dibenzo[*b*,*d*]azepine (3d')

Yellow solid (272.6 mg, 66% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.54 – 7.49 (m, 1H), 7.44 (dd, *J* = 7.8, 1.1 Hz, 1H), 7.30 (td, *J* = 7.6, 1.3 Hz, 1H), 7.21 – 7.14 (m, 5H), 7.11 – 7.04 (m, 4H), 6.95 – 6.89 (m, 2H), 6.84 (dd, *J* = 7.9, 1.1 Hz, 1H), 6.63 – 6.56 (m, 1H), 4.66 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 151.9, 147.1, 140.2, 140.0, 139.3, 138.7, 133.5, 133.1, 132.9, 132.3, 130.3, 130.2, 129.9, 129.5, 128.8, 128.3, 128.1, 127.4, 127.0, 125.2, 124.5, 119.8. IR (KBr): 3366, 2918, 1588, 1478, 1262, 827, 750 cm⁻¹. HRMS (ESI) m/z calculated for C₂₆H₁₈Cl₂N [M+H]⁺ 414.0816, found 414.0814.



2-(*Tert*-butyl-6,7-bis(4-(trifluoromethyl)phenyl)-5*H*-dibenzo[*b*,*d*]azepine (3e')

Yellow solid (424.2 mg, 79% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.53 (d, *J* = 1.6 Hz, 1H), 7.49 (d, *J* = 8.2 Hz, 3H), 7.37 (d, *J* = 8.5 Hz, 2H), 7.33 (d, *J* = 7.5 Hz, 1H), 7.28 (s, 1H), 7.26 – 7.25 (m, 1H), 7.21 (dd, *J* = 8.4, 2.2 Hz, 1H), 7.16 (d, *J* = 8.3 Hz, 1H), 7.12 (d, *J* = 8.1 Hz, 2H), 6.76 (d, *J* = 7.9 Hz, 1H), 6.53 (d, *J* = 8.2 Hz, 1H), 4.68 (s, 1H), 1.39 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 147.9, 146.5, 146.4, 143.5, 142.3, 139.6, 138.7, 131.2, 130.9, 129.3, 128.8, 128.6 (q, *J* = 32.6 Hz), 127.5 (q, *J* = 32.6 Hz), 127.3, 126.5, 126.3, 125.9, 124.6 (q, *J* = 7.2 Hz), 124.3, 124.0, 123.7 (q, *J* = 3.5 Hz), 123.0 (q, *J* = 271.9 Hz), 122.8 (q, *J* = 272.2 Hz), 118.4, 33.4, 30.4. ¹⁹F NMR (376 MHz, CDCl₃): δ -62.35, -62.60. IR (KBr): 3364, 3059, 2962, 1613, 1325, 1260, 745 cm⁻¹. HRMS (ESI) m/z calculated for C₃₂H₂₆F₆N [M+H]⁺ 538.1969, found 538.1969.



Diethyl 4,4'-(5H-dibenzo[b,d]azepine-6,7-diyl)dibenzoate (3f')

Yellow solid (410.8 mg, 84% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.88 (d, *J* = 8.2 Hz, 2H), 7.78 (d, *J* = 8.3 Hz, 2H), 7.57 – 7.51 (m, 1H), 7.46 (d, *J* = 7.7 Hz, 1H), 7.31 (t, *J* = 7.6 Hz, 1H), 7.21 – 7.13 (m, 5H), 7.07 (d, *J* = 8.3 Hz, 2H), 6.80 (d, *J* = 7.8 Hz, 1H), 6.60 – 6.56 (m, 1H), 4.77 (s, 1H), 4.33 (dq, *J* = 12.3, 7.1 Hz, 4H), 1.36 (dt, *J* = 8.9, 7.2 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 166.4, 166.0, 151.7, 147.7, 145.7, 144.3, 140.2, 139.9, 133.1, 131.6, 130.4, 130.3, 129.9, 129.6, 129.1, 128.5, 128.3, 128.1, 127.6, 127.1, 125.8, 124.6, 119.9, 61.1, 60.9, 14.3. IR (KBr): 3346, 3057, 2982, 1715, 1606, 1275, 761, 709 cm⁻¹. HRMS (ESI) m/z calculated for C₃₂H₂₈NO₄ [M+H]⁺ 490.2018, found 490.2009.



6,7-Di([1,1'-biphenyl]-3-yl)-2-(tert-butyl)-5H-dibenzo[b,d]azepine (3g')

Yellow solid (431.3 mg, 78% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.55 (d, J = 2.1 Hz, 1H), 7.52 – 7.47 (m, 1H), 7.43 (d, J = 7.8 Hz, 2H), 7.37 – 7.28 (m, 14H), 7.24 – 7.15 (m, 4H), 7.07 (d, J = 7.7 Hz, 1H), 7.01 (d, J = 7.8 Hz, 1H), 6.58 (d, J = 8.2 Hz, 1H), 4.86 (s, 1H), 1.39 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 149.7, 148.5, 147.0, 141.8, 141.2, 141.1, 140.9, 140.7, 140.6, 132.6, 131.1, 130.8, 130.5, 129.8, 129.0, 128.8, 128.6, 128.2, 127.8, 127.5, 127.4, 127.2, 127.1, 126.9, 126.6, 126.5, 126.1, 126.0, 125.6, 125.5, 125.4, 125.1, 125.0, 119.4, 34.5, 31.6. IR (KBr): 3436, 3032, 2958, 1632, 1470, 1313, 1267, 756 cm⁻¹. HRMS (ESI) m/z calculated for C₄₂H₃₆N [M+H]⁺ 554.2848, found 554.2836.



2-(*Tert*-butyl)-6,7-bis(3-fluorophenyl)-5*H*-dibenzo[*b*,*d*]azepine (3h')

Yellow solid (380.2 mg, 87% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.54 (d, J = 2.2 Hz, 1H), 7.48 (dd, J = 7.8, 0.9 Hz, 1H), 7.32 (td, J = 7.7, 1.2 Hz, 1H), 7.25 – 7.14 (m, 3H), 7.08 (dd, J = 14.0, 8.0 Hz, 1H), 6.96 (d, J = 7.7 Hz, 1H), 6.94 – 6.85 (m, 3H), 6.82 (dd, J = 8.0, 1.9 Hz, 2H), 6.80 – 6.73 (m, 1H), 6.55 (d, J = 8.2 Hz, 1H), 4.69 (s, 1H), 1.40 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 162.4 (d, J = 247.3 Hz), 162.3 (d, J = 245.8 Hz), 149.2, 147.3 (d, J = 1.8 Hz), 147.1, 143.0 (d, J = 7.8 Hz), 142.1 (d, J = 7.5 Hz), 140.5, 140.0, 132.3, 130.3, 130.2, 130.1, 129.8, 129.1 (d, J = 8.5 Hz), 127.5 (d, J = 2.7 Hz), 127.3, 126.9, 125.2, 124.7 (d, J = 1.8 Hz), 123.8 (d, J = 2.9 Hz), 119.3, 118.4 (d, J = 21.1 Hz), 115.1 (d, J = 21.8 Hz), 114.6 (d, J = 21.0 Hz), 113.4 (d, J = 20.9 Hz), 34.4, 31.5. ¹⁹F NMR (376 MHz, CDCl₃): δ -111.96, -113.81. IR (KBr): 3373, 3059, 2961, 1643, 1476, 1393, 1265, 754 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₆F₂N [M+H]⁺ 438.2033, found 438.2033.



3,3'-(2-(Tert-butyl)-5H-dibenzo[b,d]azepine-6,7-diyl)dibenzonitrile (3i')

Yellow solid (207.5 mg, 46% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.54 – 7.42 (m, 3H), 7.40 – 7.28 (m, 5H), 7.24 – 7.11 (m, 5H), 6.70 (d, *J* = 7.2 Hz, 1H), 6.50 (d, *J* = 8.2 Hz, 1H), 4.62 (s, 1H), 1.34 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 148.7, 147.6, 146.9, 141.8, 140.8, 140.6, 139.0, 136.0, 134.9, 132.6, 132.1, 131.6, 131.5, 130.4, 130.1, 130.0, 129.7, 128.8, 127.9, 127.5, 127.1, 125.5, 124.8, 119.5, 118.4, 118.0, 112.9, 112.1, 34.5, 31.4. IR (KBr): 3354, 3061, 2959, 2230, 1606, 1475, 1264, 752 cm⁻¹. HRMS (ESI) m/z calculated for C₃₂H₂₆N₃ [M+H]⁺ 452.2127, found 452.2126.



2-(Tert-butyl)-6,7-bis(3-fluorophenyl)-5H-dibenzo[b,d]azepine (3j')

Yellow solid (384.6 mg, 88% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.50 (d, J = 2.0 Hz, 1H), 7.47 (d, J = 7.7 Hz, 1H), 7.30 (td, J = 7.6, 1.2 Hz, 1H), 7.21 – 7.14 (m, 3H), 7.13 – 7.07 (m, 3H), 6.99 (t, J = 8.7 Hz, 1H), 6.92 – 6.83 (m, 4H), 6.54 (d, J = 8.2 Hz, 1H), 4.71 (s, 1H), 1.38 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 160.5 (d, J = 245.8 Hz), 159.2 (d, J = 247.0 Hz), 149.5, 146.9, 144.4, 140.4, 139.6, 133.2 (d, J = 3.0 Hz), 132.4, 130.4 (d, J = 3.5 Hz), 129.9, 129.7 (d, J = 7.9 Hz), 129.2, 128.8 (d, J = 8.1 Hz), 128.4 (d, J = 16.2 Hz), 127.5 (d, J = 17.1 Hz), 127.4, 127.3, 126.9, 125.0, 123.8 (d, J = 3.1 Hz), 123.5 (d, J = 3.4 Hz), 121.3, 119.3, 115.6 (d, J = 21.7 Hz), 115.2 (d, J = 22.4 Hz), 34.4, 31.5. ¹⁹F NMR (376 MHz, CDCl₃): δ -112.72, -112.83. IR (KBr): 3435, 3062, 2959, 1615, 1486, 1394, 1265, 755 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₆F₂N [M+H]⁺ 438.2033, found 438.2032.



2-Isopropyl-6,7-di(thiophen-3-yl)-5*H*-dibenzo[*b*,*d*]azepine (3k')

Yellow solid (259.4 mg, 65% yield). ¹H NMR (400 MHz, C_6D_6): δ 7.46 – 7.39 (m, 2H), 7.19 (dd, J = 7.9, 1.3 Hz, 1H), 7.09 (td, J = 7.5, 1.4 Hz, 1H), 7.00 (td, J = 7.7, 1.4 Hz, 1H), 6.89 (dd, J = 8.0, 2.0 Hz, 1H), 6.69 – 6.62 (m, 3H), 6.62 – 6.58 (m, 2H), 6.55 (dd, J = 5.0, 1.3 Hz, 1H), 6.19 (d, J = 8.0 Hz, 1H), 4.43 (s, 1H), 2.75 (dt, J = 13.7, 6.9 Hz, 1H), 1.18 (d, J = 6.9 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 149.9, 144.7, 143.6, 141.1, 141.0, 140.6, 139.9, 133.1, 130.5, 129.9, 129.7, 128.1, 127.4, 127.0, 126.8, 126.1, 125.3, 124.6, 124.1, 123.4, 120.8, 119.6, 33.6, 24.2. IR (KBr): 3366, 3101, 2958, 1638, 1462, 1263, 735 cm⁻¹. HRMS (ESI) m/z calculated for $C_{25}H_{22}NS_2$ [M+H]⁺ 400.1194, found 400.1206.



Ethyl 2-(tert-butyl)-7-butyl-6-phenyl-5H-dibenzo[b,d]azepine-9-carboxylate (3l')

One regioisomer was isolated, and the other possible isomer was not found in the crude ¹H NMR. Yellow solid (263.1 mg, 58% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.12 (s, 1H), 7.95 (d, *J* = 8.0 Hz, 1H), 7.53 - 7.34 (m, 7H), 7.28 (s, 1H), 6.74 (d, J = 8.2 Hz, 1H), 4.56 (s, 1H), 4.42 (dd, J = 14.2, 7.1 Hz, 2H), 2.56 - 2.40 (m, 2H), 1.43 (t, J = 6.8 Hz, 3H), 1.38 (s, 9H), 1.15 - 1.09 (m, 2H), 1.03 - 0.92 (m, 2H), 0.58 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 166.8, 151.5, 147.6, 146.6, 145.9, 141.2, 141.1, 132.1, 130.0, 129.1, 128.7, 128.6, 128.0, 127.3, 126.9, 125.5, 122.2, 118.6, 60.9, 34.4, 31.5, 31.4, 31.3, 21.8, 14.4, 13.7. IR (KBr): 3449, 3059, 2960, 1709, 1630, 1461, 1389, 1288, 748 cm⁻¹. HRMS (ESI) m/z calculated for $C_{31}H_{36}NO_2 [M+H]^+ 454.2746$, found 454.2757.

D. Preliminary studies on the stability of enamine 3a:

(I) Stability of enamine 3a towards silica gel:



To a solution of 3a (103.6 mg, 0.30 mmol) in DCM (3.0 mL), silica gel (518 mg) was added. The resulting mixture was stirred at room temperature for 24 h, filtered, and concentrated in vacuo. The residue was purified by basic alumina chromatography (petroleum ether/ethyl acetate = 50:1) to afford the imine product 4a in 14% yield (14.6 mg). The spectral data of 4a are in accordance with the literature values.6

(II) Stability of enamine 3a towards the air:



The solution of 3a (103.6 mg, 0.30 mmol) in DCM (3.0 mL) was stirred under the air at room temperature for 24 h. The mixture was then purified by flash chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) to afford peroxide **5a** in 22% yield (24.9 mg). ¹H NMR (400 MHz, CDCl₃): δ 8.18 – 8.10 (m, 1H), 7.90 – 7.82 (m, 2H), 7.74 – 7.70 (m, 1H), 7.70 – 7.62 (m, 1H), 7.55 (td, *J* = 7.6, 1.2 Hz, 1H), 7.49 – 7.41 (m, 3H), 7.38 (d, J = 7.5 Hz, 1H), 7.21 (s, 1H), 7.13 (qd, J = 8.0, 1.5 Hz, 2H), 7.04 - 6.81 (m, 5H), 6.79 - 6.49 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 166.7, 145.3, 139.5, 138.9, 135.6, 134.6, 131.0, 129.8, 129.3, 129.0, 128.6, 128.3, 128.1, 128.0, 127.7, 127.1, 125.3, 124.3, 123.9, 91.7. IR (KBr): 3059, 2851, 1620, 1475, 1265, 733 cm⁻¹. HRMS (ESI) m/z calculated for C₂₆H₂₀NO₂ $[M+H]^+$ 378.1494, found 378.1490.

E. Catalytic results:

The chiral phosphoric acids catalyzed enantioselective tautomerization of enamines 3:



In a glovebox, a 5.0 mL vial equipped with a stir bar was charged with CPA-1 (7.2 mg, 0.02 mmol) S21

and *m*-xylene (0.34 mL), stirred for 10 min, and a *m*-xylene (0.34 mL) solution of enamine **3** (0.2 mmol) was added. The vial was immediately sealed with a Teflon screw cap and stirred at 0 $^{\circ}$ C for 40 h. The mixture was then directly chromatographed on basic (petroleum ether/ethyl acetate) to afford the desired product **4**.



6,7-Diphenyl-7*H*-dibenzo[*b*,*d*]azepine (4a)

White solid (61.4 mg, 89% yield). 93% ee, $[\alpha]_D^{17} = 474.00$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.08 (dd, *J* = 6.3, 2.9 Hz, 2H), 7.80 – 7.72 (m, 1H), 7.46 – 7.40 (m, 7H), 7.24 (d, *J* = 3.7 Hz, 1H), 7.14 (t, *J* = 7.5 Hz, 1H), 6.97 (t, *J* = 7.5 Hz, 1H), 6.94 – 6.86 (m, 3H), 6.79 – 6.71 (m, 2H), 6.03 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 166.2, 146.2, 140.4, 138.9, 137.4, 136.8, 130.9, 130.4, 129.8, 129.8, 128.7, 128.6, 128.2, 127.9, 127.8, 127.6, 127.5, 126.7, 126.3, 126.1, 124.2, 53.8. The ee of **4a** was determined by HPLC using an IB column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 0.5 mL/min, t_{minor} = 12.6 min, t_{major} = 16.8 min). The spectral data are in accordance with the literature values.⁶



2-Methyl-6,7-diphenyl-7*H*-dibenzo[*b*,*d*]azepine (4b)

White solid (68.2 mg, 95% yield). 87% ee, $[\alpha]_D^{17} = 436.86$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.06 (dd, J = 6.6, 2.4 Hz, 2H), 7.82 – 7.70 (m, 1H), 7.55 – 7.31 (m, 5H), 7.25 (d, J = 0.6 Hz, 2H), 7.13 (d, J = 8.1 Hz, 1H), 7.02 – 6.86 (m, 4H), 6.83 – 6.72 (m, 2H), 6.00 (s, 1H), 2.26 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 165.3, 144.1, 140.6, 138.8, 137.6, 136.9, 133.6, 130.6, 130.2, 129.8, 128.8, 128.7, 128.5, 128.2, 127.9, 127.8, 127.5, 126.7, 126.4, 126.2, 53.8, 21.1. The ee of compound **4b** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 95/5, flow rate = 0.5 mL/min, t_{minor} = 9.1 min, t_{major} = 10.8 min). The spectral data are in accordance with the literature values.⁶



2-Isopropyl-6,7-diphenyl-7*H*-dibenzo[*b*,*d*]azepine (4c)

White solid (74.4 mg, 96% yield). 93% ee, $[\alpha]_D^{17} = 475.66$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.09 (dd, J = 6.7, 2.9 Hz, 2H), 7.77 (d, J = 7.0 Hz, 1H), 7.52 – 7.36 (m, 6H), 7.30 – 7.26 (m, 1H), 7.14 (d, J = 8.2 Hz, 1H), 7.00 (dd, J = 8.2, 1.9 Hz, 1H), 6.92 – 6.86 (m, 3H), 6.80 – 6.70 (m, 2H), 6.02 (s, 1H), 2.90 – 2.78 (m, 1H), 1.17 (d, J = 6.9 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 165.8, 144.7, 144.5, 140.5, 138.9, 137.5, 137.3, 130.9, 130.2, 129.7, 129.6, 128.7, 128.1, 127.9, 127.8, 127.4, 126.7, 126.4, 126.2, 125.9, 125.7, 53.7, 33.8, 24.2, 23.8. IR (KBr): 3056, 2923, 1615, 1450, 1333, 1267, 747 cm⁻¹. HRMS (ESI) m/z calculated for C₂₉H₂₆N [M+H]⁺ 388.2065, found 388.2047. The ee of compound **4c** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 0.5 mL/min, t_{minor} = 9.6 min, t_{major} = 12.8 min).



2-(Tert-butyl)-6,7-diphenyl-7H-dibenzo[b,d]azepine (4d)

White solid (76.2 mg, 95% yield). 97% ee, $[\alpha]_D^{17} = 842.86$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.07 – 7.93 (m, 2H), 7.66 (d, *J* = 7.4 Hz, 1H), 7.42 – 7.30 (m, 7H), 7.05 (s, 2H), 6.78 (d, *J* = 5.2 Hz, 3H), 6.72 – 6.59 (m, 2H), 5.92 (s, 1H), 1.16 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 164.9, 145.8, 143.0, 139.4, 137.9, 136.4, 136.3, 129.5, 129.2, 128.6, 128.5, 127.6, 126.9, 126.8, 126.7, 126.3, 125.6, 124.8, 124.7, 124.3, 123.5, 52.6, 33.3, 30.2. The ee of compound **4d** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 95/5, flow rate = 0.5 mL/min, t_{minor} = 9.4 min, t_{major} = 11.3 min). The spectral data are in accordance with the literature values.⁶



2,6,7-Triphenyl-7H-dibenzo[b,d]azepine (4e)

White solid (79.2 mg, 94% yield). 93% ee, $[\alpha]_D^{17} = 523.80$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.09 (dd, J = 3.7, 2.3 Hz, 2H), 7.86 – 7.78 (m, 1H), 7.71 – 7.65 (m, 1H), 7.55 – 7.52 (m, 2H), 7.51 – 7.42 (m, 6H), 7.42 – 7.35 (m, 3H), 7.33 – 7.25 (m, 2H), 6.91 – 6.83 (m, 3H), 6.83 – 6.73 (m, 2H), 6.05 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 166.3, 145.6, 140.8, 140.4, 138.9, 137.4, 136.9, 136.7, 131.3, 130.5, 129.9, 128.8, 128.5, 128.0, 127.6, 127.2, 127.1, 127.0, 126.9, 126.7, 126.3, 126.2, 53.9. The ee of compound **4e** was determined by HPLC using an IB column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 0.5 mL/min, t_{major} = 16.2 min, t_{minor} = 18.8 min). The spectral data are in accordance with the literature values.⁶



2-Methoxy-6,7-diphenyl-7*H*-dibenzo[*b*,*d*]azepine (4f)

White solid (69.8 mg, 93% yield). 80% ee, $[\alpha]_D^{17} = 481.74$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.84 (dd, *J* = 6.1, 2.5 Hz, 2H), 7.77 – 7.65 (m, 1H), 7.40 – 7.37 (m, 2H), 7.32 – 7.24 (m, 6H), 6.95 (d, *J* = 2.8 Hz, 1H), 6.86 – 6.80 (m, 2H), 6.69 – 6.58 (m, 3H). 6.01 (s, 1H), 3.69 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 162.9, 155.6, 140.7, 140.3, 138.7, 138.5, 137.4, 137.3, 137.1, 132.8, 130.3, 130.0, 129.9, 129.6, 128.7, 128.6, 127.9, 127.8, 127.7, 127.4, 126.9, 126.7, 126.3, 115.6, 112.4, 55.6, 52.7. IR (KBr): 3058, 3019, 2926, 1614, 1269, 755. HRMS (ESI) m/z calculated for C₂₇H₂₁NO [M+H]⁺ 376.1701, found 376.1695. The ee of compound **4f** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 95/5, flow rate = 0.5 mL/min, t_{minor} = 12.6 min, t_{major} = 17.5 min).



2-Fluoro-6,7-diphenyl-7H-dibenzo[b,d]azepine (4g)

White solid (68.2 mg, 94% yield). 78% ee, $[\alpha]_D^{17} = 146.34$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.01 – 7.95 (m, 2H), 7.63 – 7.58 (m, 1H), 7.41 – 7.32 (m, 6H), 7.14 – 7.09 (m, 1H), 7.05 (dd, J = 10.0, 2.9 Hz, 1H), 6.84 (dd, J = 4.3, 2.3 Hz, 3H), 6.79 – 6.73 (m, 1H), 6.69 – 6.63 (m, 2H), 5.95 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 166.1, 158.8 (d, J = 244.1 Hz), 142.8 (d, J = 2.5 Hz), 140.2, 138.8, 137.2, 135.9 (d, J = 2.0 Hz), 132.4 (d, J = 8.0 Hz), 130.5, 130.0, 129.8, 128.9, 128.8, 128.4 (d, J = 8.6 Hz), 128.0, 127.9, 127.7, 126.6, 126.3, 114.9 (d, J = 22.6 Hz), 114.2 (d, J = 22.8 Hz), 53.6. ¹⁹F NMR (376 MHz, CDCl₃): δ -118.07. IR (KBr): 3059, 3023, 2925, 1615, 1265, 755 cm⁻¹. HRMS (ESI) m/z calculated for C₂₆H₁₉FN [M+H]⁺ 364.1502, found 364.1495. The ee of compound **4g** was determined by HPLC using an IA column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 1.0 mL/min, t_{major} = 9.5 min, t_{minor} = 11.7 min).



6,7-Diphenyl-2-(trifluoromethyl)-7*H*-dibenzo[*b*,*d*]azepine (4h)

White solid (43.0 mg, 52% yield). 72% ee, $[\alpha]_D^{17} = 127.46$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): $\delta 8.13 - 7.93$ (m, 2H), 7.69 (dd, J = 5.8, 3.2 Hz, 1H), 7.64 (s, 1H), 7.50 - 7.32 (m, 6H), 7.27 - 7.16 (m, 2H), 6.82 (dd, J = 6.6, 3.6 Hz, 3H), 6.70 - 6.59 (m, 2H), 6.02 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 167.2, 147.5, 138.6, 138.0, 135.7, 134.7, 129.9, 129.8, 128.9, 128.6, 127.9, 127.8, 127.1, 127.0, 126.7 (q, J = 268.0 Hz), 125.5, 125.4, 124.8 (q, J = 12.0 Hz), 124.4, 122.8 (q, J = 12.0 Hz), 52.7. The ee of compound **4h** was determined by HPLC using an IA column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 1.0 mL/min, t_{minor} = 7.9 min, t_{major} = 8.5 min). The spectral data are in accordance with the literature values.⁶



6,7-Diphenyl-2-(trifluoromethoxy)-7H-dibenzo[b,d]azepine (4i)

White solid (79.0 mg, 92% yield). 81% ee, $[\alpha]_D^{17} = 615.20$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.14 – 8.06 (m, 2H), 7.71 (d, *J* = 3.4 Hz, 1H), 7.54 – 7.42 (m, 6H), 7.30 (s, 1H), 7.22 (d, *J* = 8.8 Hz, 1H), 6.97 (d, *J* = 8.7 Hz, 1H), 6.92 (d, *J* = 2.9 Hz, 3H), 6.73 (s, 2H), 6.08 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 167.3, 145.0, 144.8, 139.9, 139.0, 137.0, 135.7, 132.3, 130.7, 129.9, 129.7, 129.0, 128.8, 128.1, 128.0, 127.8, 127.7, 126.7, 126.3, 120.8, 120.5 (q, *J* = 256.8 Hz), 120.2, 53.6. ¹⁹F NMR (376 MHz, CDCl₃): δ -58.01. IR (KBr): 3061, 3028, 1619, 1444, 1254, 736 cm⁻¹. HRMS (ESI) m/z calculated for C₂₇H₁₉F₃NO [M+H]⁺ 430.1419, found 430.1419. The ee of compound **4i** was determined by HPLC using an IA column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 0.5 mL/min, t_{major} = 17.0 min, t_{minor} = 18.0 min).



1-Methyl-6,7-diphenyl-7*H***-dibenzo**[*b*,*d*]azepine (4j) S24 White solid (36.0 mg, 50% yield). 72% ee, $[\alpha]_D^{17} = 423.60$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.03 (dd, J = 6.6, 3.0 Hz, 2H), 7.62 – 7.50 (m, 1H), 7.53 – 7.43 (m, 3H), 7.45 – 7.32 (m, 3H), 7.07 (d, J = 7.4 Hz, 1H), 6.99 (t, J = 7.7 Hz, 1H), 6.96 – 6.83 (m, 3H), 6.76 (dd, J = 10.9, 4.6 Hz, 3H), 5.93 (s, 1H), 2.27 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 167.4, 146.9, 140.8, 140.4, 137.4, 135.1, 134.3, 132.3, 130.9, 130.3, 129.0, 128.7, 127.8, 127.7, 127.5, 126.9, 126.6, 126.2, 126.1, 126.0, 123.0, 53.8, 22.1. HRMS (ESI) m/z calculated for C₂₇H₂₂N [M+H]⁺ 360.1752, found 360.1752. The ee of compound **4j** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 95/5, flow rate = 0.5 mL/min, t_{minor} = 9.5 min, t_{major} = 12.0 min). The spectral data are in accordance with the literature values.⁶

Tautomerization of enamines 3k by using catalytic amount of HOAc:



A 5.0 mL vial equipped with a stir bar was charged with HOAc (1.2 mg, 0.02 mmol) and *m*-xylene (0.34 mL), stirred for 10 min, and a *m*-xylene (0.34 mL) solution of enamine **3k** (74.6 mg, 0.2 mmol) was added. The vial was immediately sealed with a Teflon screw cap and stirred at 0 $^{\circ}$ C for 40 h. The mixture was then directly chromatographed on basic (petroleum ether/ethyl acetate = 50:1) to afford the desired product **4k**.



2,4-Dimethyl-6,7-diphenyl-7*H*-dibenzo[*b*,*d*]azepine (4k)

Colorless solid (70.9 mg, 95% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.18 – 8.02 (m, 2H), 7.77 – 7.60 (m, 1H), 7.53 – 7.31 (m, 6H), 7.04 (s, 1H), 6.95 – 6.79 (m, 3H), 6.66 (dd, *J* = 14.9, 11.7 Hz, 3H), 5.96 (s, 1H), 2.24 (s, 3H), 2.14 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 162.1, 141.4, 139.1, 137.6, 136.7, 136.1, 132.0, 131.8, 129.1, 129.0, 128.8, 128.6, 128.5, 127.5, 126.9, 126.7, 126.5, 126.3, 125.5, 125.0, 124.9, 52.0, 20.0, 17.7. The spectral data are in accordance with the literature values.⁶



2-(Tert-butyl)-9-methoxy-6,7-diphenyl-7H-dibenzo[b,d]azepine (41)

White solid (82.0 mg, 95% yield). 90% ee, $[\alpha]_D^{17} = 411.80$ (c = 1, CHCl₃).¹H NMR (400 MHz, CDCl₃): δ 8.06 (dd, J = 6.5, 2.8 Hz, 2H), 7.67 (d, J = 8.6 Hz, 1H), 7.53 – 7.45 (m, 3H), 7.34 (s, 1H), 7.11 (s, 2H), 7.04 (dd, J = 8.6, 2.5 Hz, 1H), 6.94 (d, J = 2.5 Hz, 1H), 6.87 (d, J = 6.8 Hz, 3H), 6.78 – 6.74 (m, 2H), 5.93 (s, 1H), 3.88 (s, 3H), 1.23 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 165.3, 159.9, 146.9, 143.8, 140.6, 140.1, 137.3, 130.8, 130.4, 130.3, 130.2, 128.7, 127.9, 127.4, 126.7, 125.9, 125.8, 125.1, 124.0, 114.7, 113.3, 55.5, 53.8, 34.4, 31.3. IR (KBr): 3006, 2955, 1609, 1456, 1322, 813, 753

cm⁻¹. HRMS (ESI) m/z calculated for $C_{31}H_{30}NO [M+H]^+ 432.2327$, found 432.2321. IR (KBr): 3059, 2955, 1615, 1456, 1265, 755 cm⁻¹. HRMS (ESI) m/z calculated for $C_{31}H_{30}NO [M+H]^+ 432.2327$, found 432.2321. The ee of compound **4I** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 0.5 mL/min, t_{minor} = 14.3 min, t_{major} = 25.6 min).



2-(*Tert*-butyl)-9-fluoro-6,7-diphenyl-7*H*-dibenzo[*b*,*d*]azepine (4m)

White solid (72.2 mg, 86% yield). 90% ee, $[\alpha]_D^{17} = 722.26$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.07 (dd, J = 3.7, 2.0 Hz, 2H), 7.74 – 7.69 (m, 1H), 7.57 – 7.44 (m, 3H), 7.36 – 7.33 (m, 1H), 7.23 – 7.10 (m, 4H), 6.89 (t, J = 3.3 Hz, 3H), 6.80 – 6.68 (m, 2H), 5.96 (s, 1H), 1.24 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 165.3, 163.0 (d, J = 248.0 Hz), 147.0, 143.9, 140.6 (d, J = 7.2 Hz), 140.2, 136.7, 133.7 (d, J = 2.9 Hz,), 131.3 (d, J = 8.3 Hz), 130.4, 129.6, 128.8, 127.9, 127.5, 126.6, 126.1, 125.9, 125.2, 124.7, 116.0 (d, J = 21.4 Hz), 114.9 (d, J = 21.2 Hz), 53.5, 34.4, 31.3. ¹⁹F NMR (376 MHz, CDCl₃): δ -115.52. IR (KBr): 3058, 2958, 1607, 1492, 1353, 1265, 753 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₇FN [M+H]⁺ 420.2128, found 420.2115. The ee of compound **4m** was determined by HPLC using an IA column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 1.0 mL/min, t_{minor} = 11.2 min, t_{major} = 13.2 min).



2-(Tert-butyl)-9-chloro-6,7-diphenyl-7H-dibenzo[b,d]azepine (4n)

White solid (75.8 mg, 87% yield). 92% ee, $[\alpha]_D^{17} = 577.80$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.07 (dd, J = 6.4, 3.0 Hz, 2H), 7.68 (d, J = 8.3 Hz, 1H), 7.53 – 7.50 (m, 3H), 7.46 (dd, J = 8.2, 1.9 Hz, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.34 (d, J = 1.9 Hz, 1H), 7.17 (dd, J = 8.4, 2.0 Hz, 1H), 7.13 (d, J = 8.4 Hz, 1H), 6.91 – 6.84 (m, 3H), 6.77 – 6.72 (m, 2H), 5.96 (s, 1H), 1.24 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 165.5, 147.1, 144.1, 140.2, 140.7, 136.6, 136.0, 134.1, 130.9, 130.5, 129.5, 129.2, 128.8, 128.0, 127.9, 127.5, 126.6, 126.1, 126.0, 125.2, 125.0, 53.3, 34.4, 31.2. IR (KBr): 3058, 2924, 1616, 1475, 1397, 1267, 755 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₇ClN [M+H]⁺ 436.1832, found 436.1822. The ee of compound **4n** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 0.5 mL/min, t_{mior} = 9.0 min, t_{major} = 11.0 min).



2-(Tert-butyl)-6,7-diphenyl-9-(trifluoromethyl)-7H-dibenzo[b,d]azepine (40)

White solid (77.0 mg, 82% yield). 87% ee, $[\alpha]_D^{17} = 428.80$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.09 (d, J = 2.7 Hz, 2H), 7.87 (d, J = 8.1 Hz, 1H), 7.74 (d, J = 8.2 Hz, 1H), 7.68 (s, 1H), 7.56

-7.48 (m, 3H), 7.39 (s, 1H), 7.26 -7.20 (m, 1H), 7.16 (d, J = 8.4 Hz, 1H), 6.93 -6.86 (m, 3H), 6.72 (d, J = 3.9 Hz, 2H), 6.09 (s, 1H), 1.25 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 165.8, 147.3, 144.4, 140.9, 140.0, 139.3, 136.5, 130.6, 130.2, 130.0 (q, J = 32.4 Hz), 129.3, 128.8, 127.9, 127.6, 126.6, 126.2 (q, J = 2.6 Hz), 126.0, 125.6, 125.5, 124.6 (q, J = 3.5 Hz), 124.3 (q, J = 272.5 Hz), 53.5, 34.5, 31.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -61.90. IR (KBr): 3019, 2957, 1617, 1480, 1321, 1266, 747 cm⁻¹. HRMS (ESI) m/z calculated for C₃₁H₂₆F₃NNa [M+Na]⁺ 492.1915, found 492.1910. The ee of compound **40** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 0.5 mL/min, t_{minor} = 7.8 min, t_{maior} = 9.3 min).



2-(Tert-butyl)-6,7-diphenyl-9-(trifluoromethoxy)-7H-dibenzo[b,d]azepine (4p)

White solid (87.4 mg, 90% yield). 91% ee, $[\alpha]_D^{17} = 501.46$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.08 – 8.05 (m, 2H), 7.75 (d, *J* = 8.6 Hz, 1H), 7.51 – 7.49 (m, 3H), 7.37 – 7.33 (m, 2H), 7.29 (d, *J* = 1.7 Hz, 1H), 7.17 (dd, *J* = 8.4, 2.1 Hz, 1H), 7.12 (d, *J* = 8.4 Hz, 1H), 6.90 – 6.87 (m, 3H), 6.74 – 6.70 (m, 2H), 5.99 (s, 1H), 1.23 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 165.4, 149.2, 147.2, 144.1, 140.4, 140.1, 136.5, 136.2, 131.0, 130.5, 129.3, 128.8, 127.8, 127.5, 126.6, 126.3, 126.0, 125.3, 125.1, 121.6, 120.6 (d, *J* = 257.6 Hz), 120.0, 53.4, 34.4, 31.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -57.64. IR (KBr): 3045, 2956, 1615, 1490, 1258, 756 cm⁻¹. HRMS (ESI) m/z calculated for C₃₁H₂₇F₃NO [M+H]⁺ 486.2045, found 486.2051. The ee of compound **4p** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 95/5, flow rate = 0.5 mL/min, t_{minor} = 7.5 min, t_{major} = 8.4 min).



Ethyl 2-(*tert*-butyl)-6,7-diphenyl-7*H*-dibenzo[*b*,*d*]azepine-9-carboxylate (4q)

White solid (87.0 mg, 92% yield). 85% ee, $[\alpha]_D^{17} = 587.00$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.16 (dd, *J* = 8.1, 1.7 Hz, 1H), 8.14 – 8.05 (m, 3H), 7.83 (d, *J* = 8.1 Hz, 1H), 7.55 – 7.47 (m, 3H), 7.41 (d, *J* = 2.0 Hz, 1H), 7.21 (dd, *J* = 8.4, 2.1 Hz, 1H), 7.16 (d, *J* = 8.4 Hz, 1H), 6.91 – 6.81 (m, 3H), 6.76 – 6.68 (m, 2H), 6.12 (s, 1H), 4.44 (q, *J* = 7.1 Hz, 2H), 1.44 (t, *J* = 7.1 Hz, 3H), 1.26 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 166.5, 166.1, 147.2, 144.5, 141.8, 140.2, 139.0, 136.8, 130.8, 130.5, 129.9, 129.8, 129.7, 128.8, 128.0, 127.5, 126.7, 126.1, 126.0, 125.5, 125.4, 61.2, 53.5, 34.5, 31.3. IR (KBr): 3056, 2959, 1714, 1615, 1398, 1266, 742 cm⁻¹. HRMS (ESI) m/z calculated for C₃₃H₃₂NO₂ [M+H]⁺ 474.2433, found 474.2416. The ee of compound **4q** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 95/5, flow rate = 1.0 mL/min, t_{minor} = 7.5 min, t_{major} = 8.6 min).



2-(*Tert*-butyl)-6,7-diphenyl-7*H*-dibenzo[*b*,*d*]azepine-9-carbonitrile (4r)

White solid (75.8 mg, 89% yield). 95% ee, $[\alpha]_D^{17} = 577.06$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.08 (dd, J = 6.7, 2.9 Hz, 2H), 7.85 (d, J = 8.0 Hz, 1H), 7.78 – 7.69 (m, 2H), 7.57 – 7.47 (m, 3H), 7.36 (d, J = 2.1 Hz, 1H), 7.23 (dd, J = 8.4, 2.2 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 6.93 – 6.85 (m, 3H), 6.75 – 6.62 (m, 2H), 6.07 (s, 1H), 1.25 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 165.6, 147.4, 144.5, 142.0, 139.7, 139.5, 136.0, 133.0, 131.2, 130.8, 130.5, 129.0, 128.9, 127.9, 127.7, 126.5, 126.4, 126.2, 126.1, 125.3, 118.8, 111.6, 53.2, 34.5, 31.2. IR (KBr): 3059, 2957, 2227, 1616, 1484, 1265, 759 cm⁻¹. HRMS (ESI) m/z calculated for C₃₁H₂₇N₂ [M+H]⁺ 427.2174, found 427.2169. The ee of compound **4r** was determined by HPLC using an IA column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 1.0 mL/min, t_{minor} = 12.4 min, t_{major} = 14.5 min).



2-(*Tert*-butyl)-9-nitro-6,7-diphenyl-7*H*-dibenzo[*b*,*d*]azepine (4s)

White solid (82.2 mg, 92% yield). 84% ee, $[\alpha]_D^{17} = 421.86$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.40 – 8.28 (m, 2H), 8.11 (dd, *J* = 6.5, 2.8 Hz, 2H), 7.91 (d, *J* = 9.2 Hz, 1H), 7.58 – 7.48 (m, 3H), 7.40 (d, *J* = 1.9 Hz, 1H), 7.31 – 7.24 (m, 1H), 7.19 (d, *J* = 8.4 Hz, 1H), 6.95 – 6.89 (m, 3H), 6.81 – 6.63 (m, 2H), 6.18 (s, 1H), 1.26 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 165.6, 147.5, 147.4, 144.6, 143.9, 139.7, 139.6, 135.9, 130.9, 130.6, 129.0, 128.6, 128.0, 127.7, 126.5, 126.4, 126.2, 125.5, 124.5, 122.8, 53.3, 34.5, 31.2. IR (KBr): 3060, 2960, 1607, 1520, 1394, 1260, 769 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₇N₂O₂ [M+H]⁺ 447.2073, found 447.2074. The ee of compound **4s** was determined by HPLC using an IA column (*n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, t_{minor} = 5.9 min, t_{major} = 8.0 min).



2-(*Tert*-butyl)-10-fluoro-6,7-diphenyl-7*H*-dibenzo[*b*,*d*]azepine (4t)

White solid (76.2 mg, 91% yield). 94% ee, $[\alpha]_D^{17} = 625.54$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.07 (dd, J = 6.5, 3.0 Hz, 2H), 7.52 – 7.48 (m, 3H), 7.44 (dd, J = 10.0, 2.6 Hz, 1H), 7.37 (dd, J = 8.6, 5.8 Hz, 2H), 7.18 – 7.08 (m, 3H), 6.91 – 6.83 (m, 3H), 6.76 – 6.70 (m, 2H), 6.00 (s, 1H), 1.24 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 166.2, 162.3 (d, J = 245.2 Hz), 144.1, 140.2, 139.4 (d, J = 8.0 Hz), 137.2, 134.9 (d, J = 2.6 Hz), 131.1 (d, J = 8.5 Hz), 130.4, 129.6, 129.5, 128.7, 127.9, 127.4, 126.6, 126.0, 125.9, 125.3, 125.2, 116.0 (d, J = 22.2 H), 114.9 (d, J = 21.7 Hz), 52.8, 34.4, 31.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -114.96. IR (KBr): 3056, 3013, 2958, 1613, 1487, 1265, 757 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₇FN [M+H]⁺ 420.2128, found 420.2120. The ee of compound **4t** was determined by HPLC using an IA column (*n*-hexane/*i*-PrOH = 95/5, flow rate = 1.0 mL/min, t_{minor} = 6.2 min, t_{major} = 12.8 min).



2-(Tert-butyl)-11-chloro-6,7-diphenyl-7H-dibenzo[b,d]azepine (4u)

White solid (81.8 mg, 94% yield). 94% ee, $[\alpha]_D^{17} = 765.20$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.06 (dd, *J* = 6.6, 2.9 Hz, 2H), 7.57 – 7.47 (m, 5H), 7.31 (d, *J* = 4.8 Hz, 2H), 7.12 – 7.05 (m, 2H), 6.90 – 6.85 (m, 3H), 6.76 – 6.71 (m, 2H), 5.94 (s, 1H), 1.21 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 167.5, 145.5, 144.9, 142.8, 140.1, 136.7, 134.7, 134.3, 130.5, 130.2, 128.7, 128.5, 128.1, 127.8, 127.5, 127.0, 126.4, 125.9, 124.9, 124.6, 53.7, 34.3, 31.1. IR (KBr): 3059, 2960, 1618, 1493, 1262, 750 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₇ClN [M+H]⁺ 436.1832, found 436.1820. The ee of compound **4u** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 0.5 mL/min, t_{minor} = 9.3 min, t_{major} = 12.0 min).



2-(*Tert*-butyl)-6,7-di-*p*-tolyl-7*H*-dibenzo[*b*,*d*]azepine (4a')

White solid (80.8 mg, 94% yield). 93% ee, $[\alpha]_D^{17} = 600.40$ (c = 1, CHCl₃).¹H NMR (400 MHz, CDCl₃): δ 7.99 (d, *J* = 8.1 Hz, 2H), 7.75 (d, *J* = 7.2 Hz, 1H), 7.53 – 7.37 (m, 4H), 7.30 (d, *J* = 8.0 Hz, 2H), 7.15 (dt, *J* = 14.3, 5.2 Hz, 2H), 6.68 (d, *J* = 8.0 Hz, 2H), 6.62 (d, *J* = 7.9 Hz, 2H), 5.97 (s, 1H), 2.43 (s, 3H), 2.08 (s, 3H), 1.26 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 166.1, 146.6, 144.3, 140.5, 139.3, 137.8, 137.5, 135.2, 134.4, 130.7, 129.6, 129.5, 129.4, 128.0, 127.9, 127.8, 127.6, 126.6, 125.7, 125.4, 124.6, 53.3, 34.4, 31.3, 21.5, 20.7. IR (KBr): 3041, 2959, 1610, 1467, 1325, 1267, 755 cm⁻¹. HRMS (ESI) m/z calculated for C₃₂H₃₂N [M+H]⁺ 430.2535, found 430.2517. The ee of compound **4a'** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 95/5, flow rate = 0.5 mL/min, t_{major} = 9.5 min, t_{minor} = 12.5 min).



2-(*Tert*-butyl)-6,7-bis(4-methoxyphenyl)-7*H*-dibenzo[*b*,*d*]azepine (4b')

White solid (87.6 mg, 95% yield). 95% ee, $[\alpha]_D^{17} = 497.86$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.07 – 8.02 (m, 2H), 7.74 (dd, *J* = 7.5, 1.3 Hz, 1H), 7.50 – 7.41 (m, 2H), 7.41 – 7.36 (m, 2H), 7.15 (dd, *J* = 8.4, 2.2 Hz, 1H), 7.10 (d, *J* = 8.4 Hz, 1H), 7.02 – 6.95 (m, 2H), 6.63 (d, *J* = 8.0 Hz, 2H), 6.43 – 6.35 (m, 2H), 5.94 (s, 1H), 3.87 (s, 3H), 3.58 (s, 3H), 1.25 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 165.4, 161.4, 157.6, 146.4, 144.2, 139.2, 137.5, 133.1, 130.6, 129.7, 129.6, 129.5, 129.4, 127.9, 127.8, 127.6, 125.7, 125.3, 124.6, 113.9, 112.7, 55.4, 55.1, 52.7, 34.4, 31.3. IR (KBr): 3051, 2924, 1606, 1509, 1460, 1251, 738 cm⁻¹. HRMS (ESI) m/z calculated for C₃₂H₃₂NO₂ [M+H]⁺ 462.2433, found 462.2420.

The ee of compound **4b'** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 95/5, flow rate = 1.0 mL/min, $t_{\text{minor}} = 11.2 \text{ min}$, $t_{\text{major}} = 12.5 \text{ min}$).



2-(Tert-butyl)-6,7-bis(4-fluorophenyl)-7H-dibenzo[b,d]azepine (4c')

White solid (77.8 mg, 89% yield). 94% ee, $[\alpha]_D^{17} = 489.54$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.13 – 8.00 (m, 2H), 7.77 – 7.72 (m, 1H), 7.52 –7.42 (m, 2H), 7.39 (dd, *J* = 4.1, 1.9 Hz, 2H), 7.20 – 7.06 (m, 4H), 6.67 (dd, *J* = 7.9, 5.5 Hz, 2H), 6.55 (t, *J* = 8.7 Hz, 2H), 5.90 (s, 1H), 1.25 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 165.5, 164.2 (d, *J* = 251.1 Hz), 161.1 (d, *J* = 244.5 Hz), 147.2, 143.8, 138.6, 137.3, 136.4 (d, *J* = 3.1 Hz), 132.9 (d, *J* = 3.2 Hz), 130.5, 130.0 (d, *J* = 8.6 Hz), 129.8, 129.4, 128.2, 128.1, 128.0, 125.7, 125.4, 124.8, 115.7 (d, *J* = 21.7 Hz), 114.1 (d, *J* = 21.4 Hz), 52.8, 34.5, 31.3. ¹⁹F NMR (376 MHz, CDCl₃): δ -110.22, -117.21. IR (KBr): 3066, 2924, 1608, 1504, 1224, 727 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₆F₂N [M+H]⁺ 438.2033, found 438.2028. The ee of compound **4c'** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 95/5, flow rate = 1.0 mL/min, t_{major} = 11.2 min, t_{minor} = 12.5 min).



6,7-Bis(4-chlorophenyl)-7*H*-dibenzo[*b*,*d*]azepine (4d')

White solid (70.2 mg, 85% yield). 80% ee, $[\alpha]_D^{17} = 415.00$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.00 (dd, J = 14.6, 12.7 Hz, 2H), 7.75 (dd, J = 7.2, 1.8 Hz, 1H), 7.55 – 7.44 (m, 5H), 7.42 – 7.38 (m, 1H), 7.27 – 7.15 (m, 2H), 7.06 – 6.99 (m, 1H), 6.91 – 6.85 (m, 2H), 6.66 (dd, J = 8.5, 1.0 Hz, 2H), 5.90 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 164.1, 145.8, 138.4, 138.3, 136.8, 136.7, 135.7, 131.9, 130.7, 130.0, 129.6, 129.2, 129.0, 128.6, 128.5, 128.2, 127.9, 127.8, 127.7, 126.3, 124.7, 52.8. IR (KBr): 3061, 2923, 1617, 1432, 1091, 762 cm⁻¹. HRMS (ESI) m/z calculated for C₂₆H₁₈Cl₂N [M+H]⁺ 414.0816, found 414.0816. The ee of compound **4d'** was determined by HPLC using an IB column (*n*-hexane/*i*-PrOH = 95/5, flow rate = 0.5 mL/min, t_{minor} = 11.9 min, t_{major} = 15.7 min).



2-(Tert-butyl)-6,7-bis(4-(trifluoromethyl)phenyl)-7H-dibenzo[b,d]azepine (4e')

White solid (88.0 mg, 82% yield). 95% ee, $[\alpha]_D^{17} = 534.74$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.19 (d, J = 8.2 Hz, 2H), 7.76 (d, J = 8.3 Hz, 3H), 7.57 – 7.48 (m, 2H), 7.48 – 7.43 (m, 1H), 7.36 (d, J = 2.0 Hz, 1H), 7.19 (dd, J = 8.4, 2.1 Hz, 1H), 7.12 (dd, J = 8.4, 2.3 Hz, 3H), 6.83 (d, J = 8.1

Hz, 2H), 5.96 (s, 1H), 1.22 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 163.6, 147.9, 143.8, 143.1, 141.3, 138.3, 137.2, 132.1 (q, *J* = 32.7 Hz), 130.5, 129.9, 129.2, 128.5, 128.4 (q *J* = 32.4 Hz), 128.3, 128.1, 127.0, 125.8, 125.7 (q, *J* = 3.8 Hz), 125.4, 125.1, 124.3 (q, *J* = 3.4 Hz), 124.0 (q, *J* = 272.2 Hz), 123.9 (q, *J* = 271.9 Hz), 53.1, 34.5, 31.1. ¹⁹F NMR (376 MHz, CDCl₃): δ -62.74. IR (KBr): 3055, 2925, 1618, 1462, 1322, 1266, 756 cm⁻¹. HRMS (ESI) m/z calculated for C₃₂H₂₆F₆N [M+H]⁺ 538.1969, found 538.1968. The ee of compound **4e'** was determined by HPLC using an IB column (*n*-hexane/*i*-PrOH = 99/1, flow rate = 0.5 mL/min, t_{major} = 11.2 min, t_{minor} = 12.5 min).



Diethyl 4,4'-(7H-dibenzo[b,d]azepine-6,7-diyl)-dibenzoate (4f')

White solid (88.0 mg, 90% yield). 82% ee, $[\alpha]_D^{17} = 434.94$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.18 – 8.12 (m, 4H), 7.76 (dd, *J* = 5.9, 3.0 Hz, 1H), 7.59 (d, *J* = 8.4 Hz, 2H), 7.55 – 7.41 (m, 4H), 7.24 (d, *J* = 8.0 Hz, 1H), 7.19 – 7.13 (m, 1H), 7.03 – 6.95 (m, 1H), 6.81 (d, *J* = 8.1 Hz, 2H), 6.01 (s, 1H), 4.42 (q, *J* = 7.1 Hz, 2H), 4.25 (q, *J* = 7.1 Hz, 2H), 1.42 (t, *J* = 7.1 Hz, 3H), 1.30 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 166.3, 166.1, 164.4, 145.8, 143.8, 142.6, 138.2, 136.7, 132.1, 130.7, 130.1, 130.0, 129.6, 128.9, 128.7, 128.6, 128.4, 128.3, 127.9, 127.8, 126.5, 126.4, 124.9, 61.3, 60.8, 53.6, 14.3, 14.2. IR (KBr): 3061, 2981, 1716, 1610, 1446, 1276, 734 cm⁻¹. HRMS (ESI) m/z calculated for C₃₂H₂₈NO₄ [M+H]⁺ 490.2018, found 490.2012. The ee of compound **4f'** was determined by HPLC using an IA column (*n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, t_{minor} = 9.0 min, t_{major} = 34.9 min).



6,7-Di([1,1'-biphenyl]-3-yl)-2-(tert-butyl)-7H-dibenzo[b,d]azepine (4g')

White solid (100.6 mg, 91% yield). 93% ee, $[\alpha]_D^{17} = 595.14$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.21 (d, *J* = 1.6 Hz, 1H), 7.98 (d, *J* = 7.7 Hz, 1H), 7.70 (d, *J* = 7.7 Hz, 1H), 7.62 (d, *J* = 7.7 Hz, 1H), 7.58 (dd, *J* = 5.3, 4.2 Hz, 2H), 7.47 (td, *J* = 7.7, 2.2 Hz, 1H), 7.43 – 7.32 (m, 6H), 7.31 – 7.21 (m, 3H), 7.20 – 7.14 (m, 3H), 7.13 – 7.05 (m, 2H), 6.99 (d, *J* = 6.9 Hz, 1H), 6.90 (td, *J* = 7.6, 2.1 Hz, 1H), 6.82 (s, 1H), 6.74 (d, *J* = 7.6 Hz, 1H), 6.03 (s, 1H), 1.12 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 165.7, 147.0, 144.2, 141.8, 141.3, 140.9, 140.8, 140.4, 138.8, 138.0, 137.5, 130.7, 129.7, 129.6, 129.2, 129.1, 128.9, 128.5, 128.2, 127.9, 127.8, 127.6, 127.4, 127.1, 127.0, 126.9, 126.8, 126.0, 125.9, 125.8, 125.2, 124.9, 124.8, 53.8, 34.5, 31.3 IR (KBr): 3056, 2960, 1607, 1479, 1266, 754 cm⁻¹. HRMS (ESI) m/z calculated for C₄₂H₃₆N [M+H]⁺ 554.2848, found 554.2838. The ee of compound **4g'** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 0.5 mL/min, t_{minor} = 9.5 min, t_{major} = 11.8 min).



2-(Tert-butyl)-6,7-bis(3-fluorophenyl)-7H-dibenzo[b,d]azepine (4h')

White solid (77.0 mg, 88% yield). 90% ee, $[\alpha]_D^{17} = 677.60$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.87 (d, J = 7.8 Hz, 1H), 7.78 (t, J = 9.4 Hz, 2H), 7.55 – 7.37 (m, 5H), 7.19 (td, J = 8.6, 2.1 Hz, 2H), 7.14 (d, J = 8.4 Hz, 1H), 6.85 (dd, J = 14.1, 7.9 Hz, 1H), 6.56 (dd, J = 12.8, 7.8 Hz, 2H), 6.39 (d, J = 10.4 Hz, 1H), 5.91 (s, 1H), 1.26 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 163.8, 163.7, 163.1 (d, J = 246.5 Hz), 162.3 (d, J = 245.1 Hz), 147.5, 143.7, 142.3 (d, J = 7.1 Hz), 139.8 (d, J = 7.2 Hz), 138.2, 137.3, 130.6, 130.2 (d, J = 8.1 Hz), 129.8, 129.4, 128.8 (d, J = 8.3 Hz), 128.3, 128.2, 125.8, 125.4, 124.9, 123.3 (d, J = 2.8 Hz), 122.4 (d, J = 2.7 Hz), 117.3 (d, J = 21.4 Hz), 114.9 (d, J = 22.9 Hz), 113.9 (d, J = 22.6 Hz), 112.8 (d, J = 21.2 Hz), 53.1, 34.5, 31.3. ¹⁹F NMR (376 MHz, CDCl₃): δ -112.17, -114.40. IR (KBr): 3063, 2960, 1611, 1482, 1323, 1263, 757 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₆F₂N [M+H]⁺ 438.2033, found 438.2033. The ee of **4h'** was determined by HPLC using an IA column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 0.5 mL/min, t_{minor} = 14.8 min, t_{major} = 19.5 min).



3,3'-(2-(Tert-butyl)-7H-dibenzo[b,d]azepine-6,7-diyl)dibenzonitrile (4i')

White solid (48.8 mg, 54% yield). 80% ee, $[\alpha]_D^{17} = 370.26$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.39 (s, 1H), 8.33 (d, *J* = 8.1 Hz, 1H), 7.80 – 7.75 (m, 2H), 7.63 (t, *J* = 7.8 Hz, 1H), 7.57 – 7.52 (m, 2H), 7.47 – 7.44 (m, 1H), 7.42 (d, *J* = 2.1 Hz, 1H), 7.22 – 7.16 (m, 2H), 7.11 (d, *J* = 8.4 Hz, 1H), 7.03 – 6.99 (m, 2H), 6.91 (s, 1H), 5.89 (s, 1H), 1.25 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 161.9, 148.4, 143.3, 140.7, 138.5, 137.2, 137.0, 133.6, 131.8, 131.5, 130.9, 130.6, 130.3, 130.1, 129.9, 129.7, 129.2, 128.8, 128.7, 128.4, 125.8, 125.5, 125.3, 118.5, 118.4, 113.3, 111.6, 52.3, 34.6, 31.2. IR (KBr): 3062, 2959, 2229, 1613, 1474, 1324, 1267, 755 cm⁻¹. HRMS (ESI) m/z calculated for C₃₂H₂₆N₃ [M+H]⁺ 452.2127, found 452.2117. The ee of compound **4i**' was determined by HPLC using an IA column (*n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, t_{minor} = 11.3 min, t_{maior} = 14.8 min).



2-(Tert-butyl)-6,7-bis(2-fluorophenyl)-7H-dibenzo[b,d]azepine (4j')

White solid (45.4 mg, 52% yield). 85% ee, $[\alpha]_D^{17} = 678.94$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.86 (t, *J* = 7.2 Hz, 1H), 7.77 (d, *J* = 6.8 Hz, 1H), 7.54 - 7.48 (m, 3H), 7.47 - 7.38 (m, 2H), 7.22 (t, *J* = 7.5 Hz, 1H), 7.19 - 7.12 (m, 3H), 6.85 (dd, *J* = 13.4, 6.5 Hz, 1H), 6.74 - 6.68 (m, 1H), 6.51

(t, J = 7.5 Hz, 1H), 6.37 (t, J = 7.9 Hz, 1H), 5.81 (s, 1H), 1.27 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 163.0, 162.9, 161.0 (d, J = 250.2 Hz), 160.3 (d, J = 246.9 Hz), 147.3, 143.3, 137.8, 137.5, 132.2 (d, J = 2.8 Hz), 131.4 (d, J = 8.5 Hz), 130.6, 130.2 (d, J = 2.4 Hz), 129.6 (d, J = 3.9 Hz), 129.4, 128.0, 127.9, 127.8 (d, J = 8.3 Hz), 125.6, 125.3, 124.7, 124.4 (d, J = 3.3 Hz), 123.6 (d, J = 13.5 Hz), 122.5 (d, J = 3.3 Hz), 116.2 (d, J = 22.8 Hz), 114.9 (d, J = 22.2 Hz), 51.8 (d, J = 5.0 Hz), 34.5, 31.3. ¹⁹F NMR (376 MHz, CDCl₃): δ -110.05, -111.34. IR (KBr): 3059, 2959, 1618, 1481, 1326, 1267, 755 cm⁻¹. HRMS (ESI) m/z calculated for C₃₀H₂₆F₂N [M+H]⁺ 438.2033, found 438.2033. The ee of compound **4j'** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 99/1, flow rate = 0.5 mL/min, t_{minor} = 10.9 min, t_{major} = 13.0 min).



2-Isopropyl-6,7-di(thiophen-3-yl)-7*H*-dibenzo[*b*,*d*]azepine (4k')

White solid (69.4 mg, 87% yield). 71% ee, $[\alpha]_D^{17} = 284.54$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.03 (d, J = 1.7 Hz, 1H), 7.77 (dd, J = 5.1, 1.2 Hz, 1H), 7.73 (dd, J = 6.1, 2.6 Hz, 1H), 7.50 – 7.39 (m, 3H), 7.36 (dd, J = 5.1, 2.9 Hz, 1H), 7.29 (d, J = 1.9 Hz, 1H), 7.15 (d, J = 8.2 Hz, 1H), 7.06 (dd, J = 8.2, 1.9 Hz, 1H), 6.85 (dd, J = 5.0, 3.0 Hz, 1H), 6.48 (dd, J = 5.0, 1.0 Hz, 1H), 6.35 (dd, J = 2.9, 1.4 Hz, 1H), 5.77 (s, 1H), 2.87 (dt, J = 13.8, 6.9 Hz, 1H), 1.20 (d, J = 6.9 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 160.0, 144.7, 144.1, 143.4, 139.1, 137.2, 137.0, 131.1, 129.8, 128.8, 128.1, 127.9, 127.8, 127.0, 126.7, 126.5, 126.4, 126.3, 125.7, 124.2, 121.6, 51.1, 33.8, 24.1, 23.9. IR (KBr): 3056, 2957, 1732, 1616, 1261, 736 cm⁻¹. HRMS (ESI) m/z calculated for C₂₅H₂₂NS₂ [M+H]⁺ 400.1194, found 400.1197. The ee of compound **4k'** was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 0.5 mL/min, t_{minor} = 11.4 min, t_{major} = 17.9 min).



Ethyl 2-(*tert*-butyl)-7-butyl-6-phenyl-7*H*-dibenzo[*b*,*d*]azepine-9-carboxylate (4l')

Compound **4**I' was isolated as an inseparable diastereomeric mixture (dr = 4:1) in 56% yield (50.7 mg).

Yellow oil. 50% ee for the major diastereomer. $[\alpha]_D^{17} = 47.66$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.96 (d, *J* = 8.2 Hz, 1H), 7.87 (dd, *J* = 9.9, 8.0 Hz, 3H), 7.70 (d, *J* = 8.2 Hz, 1H), 7.60 (s, 1H), 7.43 (d, *J* = 8.6 Hz, 1H), 7.40 – 7.29 (m, 4H), 4.60 (t, *J* = 7.9 Hz, 0.79H), 4.32 (q, *J* = 7.1 Hz, 2H), 2.98 – 2.93 (m, 0.21 H), 2.12 (s, 1H), 1.40 – 1.31 (m, 12H), 0.99 (d, *J* = 4.2 Hz, 2H), 0.56 (t, *J* = 6.8 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 165.6, 165.5, 146.5, 143.0, 139.9, 139.4, 139.2, 129.2, 129.0, 128.7, 128.5, 128.2, 127.5, 127.1, 126.9, 125.5, 124.9, 124.8, 60.0, 49.8, 33.7, 30.5, 29.3, 25.2, 21.2, 13.4, 12.5. IR (KBr): 3060, 2959, 1716, 1619, 1454, 1364, 1254, 755 cm⁻¹. HRMS (ESI) m/z calculated for C₃₁H₃₆NO₂ [M+H]⁺ 454.2746, found 454.2739. The ee of **4l'** was determined by HPLC using an IA column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 0.5 mL/min, t_{minor} = 9.8 min, t_{major} = 11.0 min).

F. Further studies on the catalytic enantioselective tautomerization of enamine 3d:

(I) Gram-scale studies:



In a glovebox, a 25.0 mL vial equipped with a stir bar was charged with **CPA-1** (104.4 mg, 0.3 mmol) and *m*-xylene (5.1 mL), stirred for 10 min, and a *m*-xylene (5.1 mL) solution of **3d** (1.20 g, 3.0 mmol) was added. The vial was immediately sealed with a Teflon screw cap and stirred at 0 \mathbb{C} for 40 h. The mixture was then directly chromatographed on basic alumina (petroleum ether/ethyl acetate = 50:1) to afford the desired product **4d** in 94% yield (1.13 g, 95% ee).

(II) Low catalyst loading studies:



In a glovebox, a 5.0 mL vial equipped with a stir bar was charged with **CPA-1** (0.7 mg, 0.002 mmol) and *m*-xylene (0.34 mL), stirred for 10 min, and a *m*-xylene (0.34 mL) solution of enamine **3d** (80.2 mg, 0.2 mmol) was added. The vial was immediately sealed with a Teflon screw cap and stirred at 0 $\$ for 40 h. The mixture was then directly chromatographed on basic alumina (petroleum ether/ethyl acetate = 50:1) to afford the desired product **4d** in 27% yield (21.6 mg, 96% ee).

G. Absolute stereochemistry assignment:



To an ethanol (10 mL) solution of **4u** (218.0 mg, 0.50 mmol), cooled at 0 °C, was sequentially added NaBH₃CN (125.6 mg, 2.0 mmol) and HOAc (180.0 mg, 3.0 mmol). The reaction mixture was then stirred at room temperature for 24 h. After the reaction completed, EtOAc (10 mL) and H₂O (20 mL) were added, the organic layer was washed several times with 1N NaOH and finally with brine and dried over Na₂SO₄, and the solvent was removed *in vacuo*. The residue was purified by flash chromatography on silica gel (petroleum ether/ethyl acetate = 20:1) to afford product **6u** in 95% yield (208.1 mg, 8:1 *dr*). The analytical sample of the major regioisomer **6u**_{major} was collected by preparative thin-layer chromatography (92% ee). $[\alpha]_D^{17} = -40.06$ (c = 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.79 (d, *J* = 2.0 Hz, 1H), 7.42 (d, *J* = 8.0 Hz, 1H), 7.31 – 7.25 (m, 1H), 7.22 – 7.06 (m, 11H), 6.82 (d, *J* = 7.8 Hz, 1H), 6.54 (d, *J* = 8.1 Hz, 1H), 5.11 (d, *J* = 12.1 Hz, 1H), 4.56 (d, *J* = 12.1 Hz, 1H), 3.31 (s, 1H), 1.43 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 144.8, 143.6, 143.0, 140.3, 138.7, 137.3, 131.9, 130.1, 129.6, 129.3, 128.8, 128.5, 128.3, 128.0, 127.3, 126.8, 126.7, 125.8, 125.5, 123.0, 72.6, 50.9, 34.5, 31.6. IR (KBr): 3360, 3061, 2962, 1602, 1394, 1260, 734 cm⁻¹. HRMS (ESI) m/z calculated for

 $C_{30}H_{29}CIN [M+H]^+ 438.1989$, found 438.1987. The ee of compound **6u**_{major} was determined by HPLC using an IC column (*n*-hexane/*i*-PrOH = 98/2, flow rate = 0.5 mL/min, t_{minor} = 11.2 min, t_{major} = 12.7 min).

H. References:

[1] I. T. Alt, B. Plietker, Angew. Chem. 2016, 128, 1542; Angew. Chem. Int. Ed. 2016, 55, 1519.

[2] M. J. Mio, L. C. Kopel, J. B. Braun, T. L. Gadzikwa, K. L. Hull, R. G. Brisbois, C. J. Markworth, P. Grieco, A. Org. Lett. 2002, 4, 3199.

[3] A.-F. Tran-Van, E. Huxol, J. M. Basler, M. Neuburger, J.-J. Adjizian, C. P. Ewels, H. A. Wegner, *Org. Lett.* **2014**, *16*, 1594.

[4] Y. Xie, Chem. Commun. 2016, 52, 12372.

[5] S. J. Hein, H. Arslan, I. Keresztes, W. R. Dichtel, Org. Lett. 2014, 16, 4416.

[6] Z. Zuo, J. Liu, J. Nan, L. Fan, W. Sun, Y. Wang, X. Luan, Angew. Chem. 2015, 127, 15606; Angew. Chem. Int. Ed. 2015, 54, 15385.

I. NMR Spectra and HPLC:





















































































































28.06 -7.73 -7.42 -7.42 -7.42 -6.96 6.76 6.76 6.76















-1.15

 $\begin{array}{c} & & & \\ & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ &$







$\int_{-6.05}^{8.10} \int_{-6.05}^{8.10} \int_{-6.05}^{8.10} \int_{-6.05}^{1.54} \int_{-6.05}^{1.54} \int_{-6.05}^{1.54} \int_{-6.05}^{1.54} \int_{-6.05}^{1.56} \int_{-$

























8.03 8.02 8.02 8.02 8.02 8.01 7.17 6.61 6.63 6.63







 $\int_{-6.08}^{8.10} \int_{-6.08}^{8.10} \int_{-6.08}^{8.10} \int_{-6.08}^{8.10} \int_{-6.08}^{-8.10} \int_{-6.08}^{-8$







-2.27







~ 8.08 2.7.67 7.58 7.68 7.68 6.04 ~ -7.04 ~ -7.04 ~ -7.04 ~ -6.81 ~ -6.81 ~ -5.65 ~ -5.65 ~ -5.65 ~ -5.95






























































S137



#	[min]		[min]	[mAU*s]	[mAU]	0/0
1	16.637	BBA	0.4676	1.03591e4	354.80176	97.5593
2	18.823	BBA	0.3848	259.15976	10.36248	2.4407





S140







S143
























mAU]	86 86
120 -	
100 -	The HPLC spectrum of the single crystal of
80 -	6u _{major} that was used for X-ray diffraction studies.
60 -	
40 -	
20 -	752
0-	
Ó	2.5 5 7.5 10 12.5 15 17.5 min

#	[min]		[min]	[mAU*s]	[mAU]	90
1	10.752	BB	0.2481	9.74523	5.91773e-1	0.2587
2	11.985	BB	0.4201	3757.54761	138.26041	99.7413